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Background: Ischemic heart disease remains the number one killer in the developed world. A 
protein transduction peptide specific for the heart capable of efficiently delivering agents of 
therapeutic potential at the time of injury, would be of immense public health significance. This 
work was undertaken to identify peptide(s) able to transduce heart tissue in vivo in a tissue-
specific manner. Biopanning was performed in cell culture followed by in vivo with an M13 
phage peptide display library. Using the heart-specific peptide, we delivered nemo-binding 
domain peptide in a murine infarct model to test if NF-κB inhibition can reduce infarct size. 
Methods and Results: A cardiomyoblast cell line, H9C2, was incubated with M13 twelve amino 
acid phage peptide display library. Internalized phage was recovered, amplified and subjected to 
a total of three rounds of in vivo biopanning where infectious, internalized phage was isolated 
from cardiac tissue following intravenous injection. After the third round, 60% of sequenced 
plaques carried the peptide sequence APWHLSSQYSRT, termed cardiac targeting peptide 
(CTP). This peptide was synthesized either fluorescently labeled, biotinylated, or in combination 
with a NEMO-binding peptide (NBD), an inhibitor of the inducible NF-kappa B Kinase (IKK). 
We demonstrate that CTP was able to transduce cardiomyocytes functionally in culture in a 
concentration and cell-type dependent manner. Mice injected with CTP showed significant 
transduction of heart tissue with minimal uptake by lung and kidney capillaries, and no uptake in 
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liver, skeletal muscle, spleen or brain. The level of heart transduction by CTP also was not 
observed with a cationic transduction domain. CTP-NBD was able to inhibit NF-κB activation in 
cell culture in a dose-dependent fashion. When administered to mice in a murine infarct model, 
CTP-NBD showed a trend towards smaller infarct size, which did not reach statistical 
significance.  
Conclusions: Biopanning using a peptide phage display library identified a peptide, termed CTP, 
able to transduce cardiomyoblast cell line in vitro, and heart tissue in vivo, efficiently and 
specifically. Administration of CTP-NBD to post-infarct mice showed a trend towards reduction 
of infarct size. CTP could be used to deliver therapeutic peptides, proteins and nucleic acid 
specifically to the heart. 
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PREFACE 
Lay Summary: Heart disease remains the number one killer in the US as well as the rest of the 
developed world, and is increasing steadily in the developing world with its industrialization. 
Hearts attacks are the commonest manifestation of it and occur when an atherosclerotic plaque 
ruptures, exposing a rough surface to the blood leading to blood clotting and the resulting clot 
completely occluding the said artery. This leads to distal heart muscle tissue being deprived of 
oxygen and injury, which if it continues unchecked, leads to irreversible muscle death. Current 
therapies revolve around opening the clogged artery as expeditiously as possible, either with clot 
busting drugs or catheters. Opening the artery exposes the jeopardized muscle to a surge of 
oxygen and generation of molecules which are harmful to the muscle as well. Many molecules 
and therapies have been tested in animal models that have shown efficacy in preventing this, but 
all suffer from the drawback of lack of an appropriate delivery model. The pathology outlined 
above occurs within hours of the ruptured plaque and the window of opportunity is measured in 
hours, with no benefit seen past 12 hours. Therefore a delivery vehicle would have to target the 
heart efficiently, within hours, to deliver ready-to-go peptides or proteins of therapeutic 
potential. Also such a mode of delivery should be specific to heart in order to reduce the amount 
of peptide/protein needed to see a beneficial effect and to potentially decrease side effects. In the 
work I will be presenting in this thesis, we have done just that. Using the well-established 
technique of phage display, we have identified a peptide that targets the heart efficiently, 
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specifically, and very rapidly, within 30 minutes. This peptide can be used as a carrier to deliver 
peptides or full-length proteins to achieve therapeutic benefit in reducing heart attack sizes and 
perhaps even for diagnostic purposes. 
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1.0  INTRODUCTION 
1.1 SCOPE OF THE PROBLEM 
Ischemic heart disease and occlusive coronary artery disease continue to be the number one killer 
in the developed world. There are an estimated 500,000 acute ST-elevation myocardial 
infarctions (MI) in the US alone each year [1], and this is becoming an increasingly significant 
problem in the developing world [2]. Current approaches for management of an acutely occluded 
coronary artery leading to an MI consist of anti-platelet and anti-thrombotic strategies with 
intervention aimed at opening the infarct-related artery in a timely fashion. Although this 
approach is able to protect cardiomyocytes from necrosis, with resulting decrease in morbidity 
and mortality, it necessitates exposing the heart to post-ischemic reperfusion injury. Limiting this 
reperfusion injury and decreasing apoptosis would ultimately lead to greater myocardial salvage 
and prevention of development of heart failure.  
Numerous animal studies have identified biological agents able to ameliorate this 
ischemia-reperfusion injury and reduce the ultimate infarct size [3-5]. The clinical application of 
these potentially effective biological therapies for cardiac conditions, like myocardial infarction, 
has been limited by efficiency and specificity of delivery of therapeutic agents. For example, for 
gene therapy approaches, plasmid delivery to the heart is very inefficient whereas there are 
significant time delays associated with cardiac gene delivery using viral-based vectors in 
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addition to issues of pre-existing neutralizing antibodies or exciting an immune responses to 
certain viral vectors. The well-characterized cell penetrating peptides, like TAT from HIV coat 
protein, homopolymers of arginine or lysine, are not cell specific and transduce hepatocytes and 
multiple other organs in addition to the heart. Identifying a peptide with transduction capabilities 
specific for the heart would allow for new approaches for effective cardiac delivery of 
therapeutics to be developed. 
1.2 PROTEIN TRANSDUCTION DOMAINS 
Protein transduction domains (PTD) or cell penetrating peptides (CPP) are small peptides able to 
transverse plasma membranes and carry peptides, full-length proteins, oligonucleotides, iron 
nanoparticles and liposomes as “cargoes”. These PTDs can be broadly classified under three 
classes; cationic or positively charged PTDs, hydrophobic or protein leader sequence-derived 
domains and peptides identified by phage display that are able to transduce cells in a cell-type 
specific manner. Interest in these moieties began with the simultaneous reports by Franckel and 
Pabo [6], and Green and Lowenstein [7], that HIV-1 TAT (transactivator of transcription) protein 
was able to cross plasma membranes. A few years following these initial reports, the 
Antennapedia homeodomain of Drosophila melanogaster was shown to act in a similar manner 
[8]. Further investigation revealed that smaller peptides derived from these larger full-length 
proteins were responsible for their transduction abilities and could carry multiple, different, full-
length proteins as cargoes [9-11]. Interest in these unique peptides has been burgeoning leading 
to identification of multiple naturally occurring [12-14] as well as engineered PTDs [15-16].  
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Multiple studies have shown the ability of PTDs to deliver peptides of therapeutic 
potential [17-18], full-length proteins [11, 19], oligonucleotide [20], 40nm iron nanoparticles 
[21-22], drugs [23],  and liposomes [24]. In addition there is intense interest in developing PTDs 
as vehicles for delivery of small interfering RNA (siRNA) in vitro [25-26] and in vivo [27-28], 
with novel strategies aimed at PTD and siRNA complex escaping the endosomal compartment 
[29-30] or increasing efficacy by avoiding the nuclear compartmentalization [30]. These selected 
number of publications, involving myriad applications of PTDs, highlight not only the interest 
but also the potential application of PTDs as delivery tools in a variety of disease models 
employing many different strategies of therapeutic potential. Although PTDs have shown the 
ability to deliver biologically active cargo in vivo, and even cross the blood-brain barrier [11], 
the lack of cell or tissue specificity seen with the cationic or hydrophobic PTDs, limits their 
therapeutic potential and would add to their toxicity limiting use in vivo. In light of these 
considerations, it has become increasingly apparent that for PTDs to be useful, it is necessary to 
identify peptides that are tissue specific in order to limit toxicity and enhance therapeutic 
potential. To identify such peptides, biopanning or phage display has emerged as a powerful 
technique. 
1.3 BIOPANNING OR PHAGE DISPLAY 
The principal underlying display technologies consist of the ability to physically link phenotypes 
of polypeptides displayed on a certain platform to their corresponding genotype. Typically the 
phenotype registered in display experiments is through physical binding and serial selection. 
Figure 1 shows the schema of available display technologies [31].   
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Figure 1. Schema of available display technologies. 
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All display platforms are based on the ability to physically link the polypeptide produced 
by a library clone to its corresponding genotype. This allows one to recover the DNA encoding 
the clone selected based on the desired polypeptide phenotype, such as binding to the target.  
The ability to modify filamentous bacteriophage to express polypeptides on the surface as 
part of the bacteriophage’s coat protein was first reported by Smith [32] in 1985. This technique 
was originally developed to map epitope-binding sites of antibodies by mapping against 
immobilized immunoglobulins. This seminal work led to phage display being utilized as a 
powerful method to detect polypeptide binding with a diverse range of biological, as well as 
technical and medical applications [33].  
A brief word on the biology of phage is warranted here. “Phages” or bacteriophage are 
prokaryotic bacterial viruses, which are the most abundant biological entities in the environment 
with estimates ranging from 1030 to 1032 and play a key role in many biological systems. 
Bacteriophages as a group are extremely diversified. The number of known phage has been 
expanding for decades at a rate of ~100/year. The Felix d’Herelle Reference Center for Bacterial 
Viruses is charged with keeping track of these. The first survey was published in 1967 with latest 
surveys made in 1995 and 2000 [34-35]. Phages are broadly classified as Tailed, Polyhedral, 
Filamentous or Pleomorphic. According to the latest electron microscopic analysis of over 500 
phages [36], the vast majority (~96%) are tailed with polyhedral, filamentous and pleomorphic 
phage comprising 3.7% of the total number of phage studied. Of these, filamentous phage has 
been studied widely for the purpose of phage display. Filamentous phage are non-lytic and leave 
the host by budding through the host plasma membrane without killing their pilli-bearing host 
bacteria, though markedly slowing it’s rate of replication. The filamentous phage best studied 
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biochemically and genetically is the M13 and its close relative fd bacteriophage. Both are F-
specific phages that infect Escherichia coli bacteria.  
M13 phage is a long, thread shaped particle, 6.5nm in diameter and 900nm in length. Its 
genome is a single-stranded, circular DNA containing 6,407 nucleotides protected by a long 
cylindrical protein coat. The most abundant coat protein is the major coat protein pVIII, of which 
~2700 molecules are present on the coat. There are only 5 copies of the minor coat protein pIII at 
one end of the phage particle, which along with 5 molecules of another minor coat protein, pVI, 
is involved in bacterial cell binding. At the other end of the phage are minor coat proteins pVII 
and PIX, which are needed for initiation and maintenance of phage assembly inside the host. 
During the assembly process the resulting fusion coat proteins are transported to the bacterial 
periplasm or inner cell membrane and incorporated into a new phage particle along with the 
single stranded DNA genome of the phage carrying the genotypic information for the displayed 
fusion protein. Figure 2 is a schematic representation of phage structure, followed by a 
diagrammatic representation of phage assembly and budding from an E. coli host cell. 
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• Dimensions:
– 6.5nm in diameter
– Length dependant on genome 
but wild type approximately 
930nm
– Mass 16.3MD of which 87% 
comprised of protein
• Genome:
– Single stranded circular DNA 
molecule, covalently closed
– Housed in a flexible protein 
cylinder
 
 
Figure 2. Structure of M13 bacteriophage.  
 
 
 
Figure 3. Assembly of phage virion and its release from E. coli cells. 
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Libraries have been constructed utilizing virtually all of the coat proteins of filamentous 
phage modified for the purpose of phage display. However the commonest filamentous phage 
libraries consist of phage with modified minor capsid protein pIII, expressing 109 peptides, or 
more, of different permutations. Filamentous phage infect pilus-positive bacteria that are not 
lysed by the infecting phage and secrete multiple, identical copies of it displaying a particular 
insert. Phage display constitutes exposing the target of interest to a large, randomized library of 
phage expressing peptides on a surface coat protein. After binding, the non-relevant phage is 
washed away, the bound phage eluted, expanded in pilli-positive host bacteria, and re-exposed to 
the target of interest. Four to six cycles of biopanning lead to adequate enrichment with the 
relevant clone phage, which can subsequently be sequenced, and the peptide motif carried as a 
fusion coat protein identified. This technique allows one to identify peptides able to bind 
immobilized targets, surfaces of different cell types and even target tissues in vivo without a 
priori knowledge of the target ligand, as outlined in the figure below. 
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Figure 4. Schematic representation of steps in screening a peptide phage display library. 
   
Initial studies utilizing phage display libraries were limited to in vitro work, phage 
display being carried out against immobilized antigen targets or cell-specific ligands. Arap and 
colleagues [37] showed the feasibility of in vivo phage display leading to identification of 
peptides homing to tumor vasculature as well as the ability to use these peptides to target anti-
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cancer therapy. Further in vivo work has clarified that not only tumor vasculature but also normal 
organs, like adipose tissue [38] and the heart [39], among other organs [40-41], bear ligands that 
can be targeted by in vivo phage display. Work in our lab has identified peptides targeting 
synoviocytes which are able to deliver therapies to synovial fibroblasts in vivo [42] as well as 
protect islet cells in a mouse model of diabetes [43]. Hence biopanning or phage display has 
evolved as a powerful technique for identification of peptides targeting not only immobilized 
antigens, but cell-specific ligands in vitro, vasculature of various organs and tissue types in vivo.    
1.4 NUCLEAR FACTOR ΚB 
NF-κB was first identified as a transcription factor binding to the intronic enhancer of the Кappa 
light chain gene in B-cells over 20 years ago [44-45]. It soon became apparent that this 
transcription factor plays a major role in orchestrating innate and adaptive immune responses 
that are key to a multicellular organism’s ability to respond to environmental, mechanical, 
chemical and microbial stresses. It also became apparent that deregulation of this transcriptional 
activity can lead to a myriad of seemingly different autoimmune diseases like rheumatoid 
arthritis, inflammatory bowel diseases, multiple sclerosis as well as cancer. A Pub Med search 
today would reveal over 30,000 papers. Therefore the review that follows will, out of necessity, 
be kept brief, and to the point as it relates to the thesis work done. 
NF-κB transcription factor is a family of five cytosolic proteins; p50, p52, p65 (RelA), c-
Rel, RelB, encoded by NFKB1, NFKB2, RELA, REL, and RELB respectively. All of them share 
an N-terminal Rel-homology domain (RHD) that is responsible for DNA binding and homo- or 
hetero-dimerization. RelA, c-Rel and RelB also contain C-terminal transcription activation 
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domains (TAD), whereas p50 and p52 do not and depend on heterodimerization with other 
subunits to lead to activation of transcription. NF-κB dimers bind to specific κB consensus 
sequences (5` - GGGRNWYYCC – 3`; where N=any base, R=purine, W=adenine or thymine, 
and Y=pyrimidine) within the promoter-enhancer regions of target genes and regulate 
transcription through recruitment of co-activators and repressors. These proteins reside in the 
cytosol in an inactive state either bound to inhibitors called IκBs or as the unprocessed or 
precursor proteins p100 and p105. In response to stimuli, p100 and p105 are processed to form 
p52 and p50 respectively. Three “classical” proteins, IκBα, IκBβ and IκBε, are characterized by 
the presence of multiple ankyrin repeats that mediate binding of NF-κB dimers and interfere with 
the nuclear localizing signal of the latter, thus keeping these proteins cytosolic and hence 
inactive.   
In response to appropriate stimuli, NF-κB activation occurs, leading to its nuclear 
accumulation. Activation of NF-κB by phosphorylation and degradation of inhibitory IκBs 
occurs in the classical or canonical pathway that comes into play in response to TNF-α or IL-1 
binding to their receptors. The classical pathway involves phosphorylation of the IκB proteins at 
specific serine residues (phosphorylation of IκBα on serine residues 32 and 36, and 
phosphorylation of IκBβ on serine residues 19 and 23), marking the protein for ubiquitination 
and subsequent degradation, with release of the inhibitory influence on the NF-κB dimers and 
their subsequent activation. This pathway centers on activation of the trimeric IκB kinase 
complex, (IKK), comprising the catalytic subunits IKKα, IKKβ and the non-catalytic subunit, 
IKKγ (also called NEMO for NF-κB essential modulator). IKKα and IKKβ share 50% sequence 
identity with 65% sequence identity of their catalytic subunits. There are some notable 
differences with IKKα having a nuclear localizing signal that is unique to it and IKKβ having a 
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C-terminal NEMO-binding domain that exhibits much greater affinity for IKKγ/NEMO than 
IKKα. IKKγ or NEMO is obligatory for classical NF-κB activation as in its absence IKK 
complex can no longer be formed or activated [46-47]. Of the two catalytic subunits, IKKβ is the 
major IκB kinase in most cell types with few exceptions, and plays a central role in the canonical 
activation pathway. In contrast IKKα is essential for activation of the alternate pathway.  
1.4.1 Classical NF-κB Activation Pathway 
As mentioned above, NF-κB activation can occur via the canonical or classical pathway, or the 
alternate pathway. Activation via the canonical pathway requires activation of the IKK complex. 
The three major IKK proteins consist of IKKα, IKKβ and IKKγ (or NEMO- NF-κB essential 
modulator) which dimerize through the leucine zipper domain which is also required for kinase 
activity. Both IKKα and IKKβ bind the third protein component of the IKK complex, NEMO, 
through the C-terminal hexa-peptide, NEMO-binding domain (NBD; Leu-Asp-Trp-Ser-Trp-
Leu). Competition experiments and biophysical analyses using the NBD peptide indicate that 
IKKβ binds to NEMO with higher affinity than IKKα. Activation of the IKK complex requires 
phosphorylation of at least one of the IKK subunits. Active IKKβ is phosphorylated on two 
serines, Ser177 and Ser181 within the activation loop of the kinase domain. Similarly IKKα is 
phosphorylated on activation loop serine residues 176 and 180. The exact mechanism of this 
activation, autophosphorylation or an upstream IKK kinase mediated phosphorylation, remains 
to be elucidated.  
Much of the current understanding of the classical pathway of NF-κB activation comes 
from studies of TNF-α signaling. TNF-α binds to two receptors, TNFR1 and TNFR2, of which 
TNFR1 binding plays a much broader role in NF-κB activation. Binding of TNF-α to its receptor 
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TNFR1 leads to recruitment of TNFR1-associated death domain protein (TRADD). Receptor 
engagement also results in a biphasic ubiquitination of RIP1, a member of related protein 
kinases. However studies of RIP1 deficient cells show that it is likely needed for a docking 
action for IKK through its interaction with IKKγ [48]. How this leads to IKK activation is 
unclear but one mechanism proposed is recruitment of MEKK3, a kinase to the TNFR1 signaling 
complex, leading to phosphorylation of the IKKα and IKKβ activation loops [49]. However 
MEKK3 is not unequivocally an essential IKK kinase and there are likely many others, like 
TAK1, and the relative importance/role of an IKK kinase is likely to be cell-dependent. TAK1 
might be recruited to the TNFR1 signaling complex via TRAF-2 dependent polyubiquitination of 
RIP1 or by more direct recruitment of TAK1 via TRAF2 or TRAF6. Although the exact nature 
and events leading to IKK activation differ depending on the stimulus (TNF-α , IL-1, antigen 
binding etc), the ultimate common path is activation of the IKKα and/or IKKβ by 
phosphorylation of serine residues in the activation loop. This activation of the IKK complex 
leads to phosphorylation of IκBα, leading to its proteasomal degradation and release of its 
inhibition of p50/p65 heterodimers, their nuclear translocation and initiation of transcriptional 
activity. This is schematically represented in the figure below (Figure 5) for TNF-α mediated 
NF-κB activation [50].    
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Figure 5. Activation of classical NF-κB signaling by TNF-a.  
 
 
 15 
Ligation of TNFR1 results in TRADD-dependent TRAF2/TRAF5 and RIP1 recruitment. 
TRAF2 causes K63-linked ubiquitination of RIP1 and also recruits IKK to the receptor complex, 
where binding of IKKγ to ubiquitinated RIP1 stabilizes IKK interaction with the receptor 
complex. This may also lead to a conformational change of the IKK complex. TAB2 and TAB3 
interact with TRAF2 and TAK1, leading to TAK1 activation that may then phosphorylate IKKβ. 
Alternatively, MEKK3, which is brought near the receptor complex presumably by RIP1 may 
also phosphorylate and activate IKK. On the other hand, IKK may also be activated by 
autophosphorylation. Activated IKK phosphorylates IκBα at specific serine residues, leading to 
the proteasome-mediated degradation of the latter. Degradation of IκBα releases the NF-κB 
heterodimers, which then migrate to the nucleus and regulate gene expression. 
1.4.2 Alternate NF-κB Activation Pathway 
NIK is an unstable protein, subject to rapid turnover in non-stimulated cells, first identified as a 
protein kinase, whose over-expression results in NF-κB activation [51]. Stimulation of B cells 
with certain TNF family members, such as CD40L, results in stabilization of NIK trans-
autophosphorylation, its subsequent accumulation leading to activation of IKKα. In the resting 
state, NIK is associated with TRAF2, TRAF3 and cIAP1/2. TRAF3 appears to function as an 
adapter linking NIK to the ubiquitin ligase complex consisting of TRAF2/cIAP1/1. This complex 
causes ubiquitination of NIK and consequent degradation. Upon cell stimulation with appropriate 
receptor-ligand binding, a protein ubiquitination cascade ensues with TRAF2 ubiquitinates 
cIAP1/2 through a K63-linkage leading to the activation of their K48-specific ubiquitin ligase 
activity towards TRAF3. This cascade leads to NIK stabilization, accumulation, and activation of 
IKKα through phosphorylation, leading to processing of p100 to its p52 residue and release of 
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RelB/p52 heterodimers allowing for nuclear translocation, as demonstrated in Figure 6 below 
[50]. 
 
 
        
Figure 6. Activation of NF-κB signaling by CD40.  
 
In resting cells (left), p100, via its C-terminal ankyrin repeats, binds and keeps RelB in 
the cytosol. NIK, which is an essential kinase involved in the phosphorylation and proteasome-
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mediated C-terminal processing of p100, is maintained at very low levels owing to rapid 
proteasome-dependent degradation. TRAF3 links NIK to an E3 complex containing TRAF2 and 
cIAP1/2, thereby promoting cIAP1/2-mediated K48-linked NIK polyubiquitination and 
proteasomal degradation. TRAF3 also undergoes a low level of K48-linked polyubiquitination 
under resting conditions. Activation of CD40 by CD40L (right) leads to recruitment of the 
cIAP1/2:TRAF2:TRAF3 complex to the receptor, where cIAP1/2 undergoes TRAF2-dependent 
K63-linked polyubiquitination. TRAF2 also undergoes K63-linked self-ubiquitination. K63-
linked ubiquitination of cIAP1/2 enhances their K48-specific E3 ubiquitin ligase activity toward 
TRAF3, leading to proteasomal degradation of the latter. As a result, TRAF3 levels in the cell 
drop below a critical threshold, and NIK can no longer be recruited to the cIAP1/2:TRAF2 
complex. This leads to stabilization and accumulation of newly synthesized NIK and its 
activation presumably via autophosphorylation, resulting in activation of IKKα. Activated IKKα 
phosphorylates p100, leading to proteasome-mediated processing of p100 to p52. C-terminal 
truncation of p100 releases the p52:RelB heterodimer, which migrates to the nucleus and 
regulates transcription of its target genes. 
Once activated, the termination of active NF-κB heterodimers is poorly understood. 
Studies have focused on upstream targets and shown that among the myriad of genes activated 
by NF-κB, IκB protein synthesis is up regulated, thus serving as a negative feedback loop. 
However terminating the activity of DNA-promoter bound NF-κB remains poorly understood 
and is a subject of active ongoing research.  
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1.5 NEMO-BINDING DOMAIN PEPTIDE 
As detailed above, activation of NF-κB, via the canonical pathway, requires activation of the 
IκB-Kinase, or IKK complex. This complex consists of three major proteins, IKKα, IKKβ and 
IKKγ, the latter also known as NEMO (NF-κB essential modulator). An elegant study by May et. 
Al. [52] revealed that this interaction occurs not only between IKKβ and NEMO, but also IKKα 
and NEMO, albeit with lesser affinity. This study also mapped the region interacting with 
NEMO to the NH2-terminal α-helical region of both IKKα and IKKβ, consisting of 6 amino 
acids, Leu-Asp-Trp-Ser-Trp-Leu, and was termed the nemo-binding domain (NBD). In the study 
a cell permeable peptide was created consisting of the Antennapedia homeodomain, a PTD, 
fused to the 11 amino acids from T735 to E745 of IKKβ. This peptide was termed NBD peptide. 
A mutant NBD peptide was also generated with W739 and W741 replaced with alanines. The 
NBD peptide inhibited in vitro interaction of IKKβ with NEMO and disrupted formation of 
endogenous IKK complexes in HeLa cells. Pre-treating HeLa cells with this NBD peptide 
inhibited TNF-α induced NF-κB activation. Interestingly, the basal NF-κB activity was enhanced 
approximately two-fold by the NBD peptide, suggesting that removal of NEMO slightly 
increases the basal activity of the IKK complex. The differential binding abilities of IKKα and 
IKKβ with NEMO were further characterized by mutational analysis showing that for IKKβ 
nemo-binding domain to interact with NEMO, the aspartate residues at 738 and two tryptophan 
residues at 739 and 741 were critical [53]. The requirement for binding to IKKα was not equally 
stringent, with the first tryptophan residue at position 740 being most important.  
Since the description of the NEMO-binding domain and generation of a small peptide 
able to inhibit IKK complex activation, this peptide has been studied in numerous animal models 
of inflammatory diseases. The original report detailed efficacy of this peptide in reducing 
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phorbol 12-myristate 13-acetate induced ear edema, repressing E-selectin expression by HUVEC 
cells in response to TNF-α, as well as decreasing peritonitis in mice injected with intraperitoneal 
zymosan [52]. Following these initial reports, the NBD peptide in association with various 
protein transduction domains (PTD-5, TAT or Antennapedia homeodomain), has been shown to 
protect pancreatic islet cells from detrimental effects of IL-1β [43], block osteoclastogenesis, 
synovial inflammation and bone erosion in inflammatory arthritis [54-55], and be beneficial in 
two different models of murine colitis [18, 56]. In addition to murine models of inflammatory 
bowel disease, NBD peptide was able to decreased bowel injury and decrease mortality in a 
neonatal rat model of necrotizing enterocolitis [57]. The table below summarizes the studies that 
have been undertaken to date utilizing NBD peptide. 
 
Table 1. Summary of studies utilizing NBD peptide. 
Authors Journal/Year Model Result 
Long, YM et. Al. 
[58] 
W J Gastro/2009 Rat/Pancreatitis ↓ Inflammation 
Ianaro, A et. Al. 
[59] 
Canc Lett/2009 Melanoma cell line ↓ Proliferation 
Dave, SH et. Al. 
[18] 
J Immun/2007 Mice/Colitis ↓ Inflammation/colitis 
Tapia, MA et. Al. 
[60] 
Cell Cycle/2007 Breast cancer cell line ↑Doxorubicin 
sensitivity 
Shibata, W et. Al. 
[56] 
J Immun/2007 Mice/Colitis ↓ Inflammation/colitis 
De Plaen, IG et. Pediat Res/2007 Rat/Necrotizing colitis ↓ Bowel Injury 
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Al. [57] 
Tas, SW et. Al. 
[61] 
Arthir Res Ther/2006 Rat/Arthritis ↓ Arthritis Severity 
van den Tweel, 
ER et. Al. [62] 
Pediat Res/2006 Rat/Cerebral ischemia ↑ Neuronal Damage 
Di Meglio, P et. 
Al. [55] 
Arthrit rheum/2005 Mice/Carrageenan-
induced paw edema 
↓ Paw Edema 
Dai, S et. Al. [54] JBC/2004 Mice/Inflammatory 
arthritis 
↓Inflammation 
↓erosions 
Biswas, DK et. 
Al. [63] 
PNAS/2004 Breast cancer cell line ↑Apoptosis/↓cell 
proliferation 
Ashikawa, K et. 
Al. [64] 
Bioch Pharma/2004 Lymphoid/myeloid 
cell line 
↓Doxorubicin 
sensitivity 
Rehaman, KK et. 
Al. [43] 
JBC/2003 Mouse islet cell line ↑Viability 
↑islet cell function 
Thomas, RP et. 
Al. [65] 
Surgery/2002 Pancreatic cancer cell 
line 
↑Apoptosis/↓cell 
viability 
 
From the foregoing studies, it would appear that the NBD peptide, with an appropriate 
protein transduction domain acting as a delivery vehicle, could be of use as a beneficial, anti-
inflammatory agent. 
Table 1 - continued 
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1.6 NF-ΚB AND THE HEART    
Many of the key elements of the canonical NF-κB pathway have been identified in cardiac 
myocytes. Exposing cardiac cells to stimuli like LPS, cytokines or reactive oxygen species as 
well as ischemia-reperfusion leads to phosphorylation and subsequent degradation of IκBα. The 
cytoplasmic to nuclear shuttling of p65/p50 heterodimers has also been confirmed in cardiac 
myocytes, using electrophoretic mobility shift assays that employed κB sequence-containing 
probes that confirmed the identity of the proteins within these complexes [66-68]. Of the 5 NF-
κB family proteins, only p65, p50, p52 and RelB have been identified in cardiac myocytes thus 
far. These family members can form heterodimers and act as transcription factors, or p50 can 
homodimerize to act as a repressor of transcription. Although detailed studies of the dimeric 
species present in the heart have not been performed, it would appear that NF-κB-dependent 
transcription activation or repression is regulated primarily by p65/p50 or p50/p50 dimers 
respectively [69-72]. As detailed earlier, NF-κB dimmers reside in the cytoplasmic compartment 
and are kept inactive by their association with inhibitor IκB proteins. Of the 8 IκB family 
members, only IκBα, IκBβ, IκBε, Bcl-3, p100 and p105 have been identified in the heart.  
Studies have revealed a role for NF-κB stimulation in macrophages in atherosclerotic 
plaques [73-75] as well as inhibition of endothelial NF-κB protecting mice from atherosclerosis 
[76]. In addition several studies have high-lighted the importance of NF-κB in generation of 
cardiac hypertrophy in response to mechanical stretch [77-78], transverse aortic banding [79], in 
response to Angiotensin II [80] with blockade of NF-κB in transgenic IκBα dominant-negative 
mice or RNA interference leading to prevention of cardiac hypertrophy and heart failure [81-84].  
The role of NF-κB appears to be quite complex in murine models of infarction or 
ischemia/reperfusion. In vivo molecular imaging utilizing transgenic mice expressing Luciferase 
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under an NF-κB promoter site revealed that post infarction NF-κB is up regulated with a peak 
occurring at day 3. After that, the activity level decreases but remains elevated for up to 8 weeks 
post-infarct (the maximum length these mice were followed) [85]. On one hand, NF-κB 
activation is necessary to generate the cardioprotective response associated with ischemic pre-
conditioning, as several groups have demonstrated that this beneficial effect is lost with 
inhibition of NF-κB signaling [72, 86-88]. On the other hand inhibiting NF-κB activation by 
using p50 knockout mice [89], over-expressing A20 (an inhibitor of NF-κB protein) [90], 
adenoviral delivery of IκB [91-92], or adenoviral delivery of MyD88 [93] led to decrease in 
infarct size in rodent models of ischemia-reperfusion or infarction. Double-stranded 
oligodeoxynucleotides with specific affinity for NF-κB used as decoys in rat hearts led to more 
rapid recovery of heart function after heart transplantation [94] and reduced infarct size in a 
murine model of ischemia-reperfusion [95]. In an isolated report, transgenic mice harboring a 
mutated form of IκBα had increased susceptibility to tissue injury after acute left anterior 
descending occlusion [96]. In addition small molecular inhibitors of NF-κB have shown 
beneficial effects in reducing infarct size in murine models [97-101]. Interestingly one group of 
researchers showed curcumin as having effective NF-κB inhibitory actions and ability to 
attenuate plasma inflammatory cytokine surge and cardiomyocyte apoptosis following cardiac 
ischemia-reperfusion [102-103]. These studies and the models they used are summarized below 
in Table 2.  
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Table 2. Summary of NF-kappa B studies with cardiac ischemia-reperfusion injury or myocardial 
infarction. 
Authors Journal/Year Model Infarct Size 
Timmers, L et. Al. 
[104] 
Circ Res/2009 p50 KO/MI/mouse ↔/Adverse 
Remodeling 
Kawano, S et. Al. 
[3] 
AJPHCP/2006 p50 KO/MI/mouse  ↔/Improved 
Remodeling 
Wakatsuki, S et. Al. 
[105] 
Expert Opin Ther/2008 IMD-0560/MI/rat ↔/Improved 
Remodeling 
Frantz, S et. Al. 
[106] 
FASEB J/2006 p50 KO/MI/mice ↔/Improved 
Remodeling 
Misra, A et. Al. [96] Circ/2003 mut IκBα/MI/mice ↑ Infarct Size 
Meili-Butz, S et. Al. 
[97] 
Eur j Pharm/2008 Dimethyl fumarate/rat/IR ↓Infarct Size 
Moss, NC et. Al. 
[98] 
AJPHCP/2007  Bay65-1942/mice/IR ↓ Infarct Size 
Frantz, S et. Al. [89] Am J Pathol/2007 p50 KO/mice/IR ↓ Infarct Size 
Trescher, K et. Al. 
[91] 
Cardiovasc Res/2006 ↑IκB expression/rat/MI Improved 
Remodeling 
Hua, F et. Al. [93] Bioch Biop Res /2005 Ad5-dnMyD88/mice/IR ↓ Infarct Size 
Yeh, CH et. Al. 
[102] 
J Surg Res/2005 Curcumin/rabbit/IR ↓Infarct Size 
Trescher, K et. Al. Eur J Cardioth Surg/2004 Ad-IκBα ↔/Improved 
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[92] Remodeling 
Onai, Y et. Al. [99] Cardiovasc Res/2004 IMD-0354/rat/IR ↓/Improved 
Remodeling 
Squadrito, F et. Al. 
[107] 
Lab Invest/2003 rAAV/IκBα/mice/IR ↓ Infarct Size 
Pye, J et. Al. [100] AJPHCP/2003 20S proteasome inh/pig/IR ↓ Infarct Size 
Kupatt, C et. Al. 
[108] 
Gene Ther/2002 NF-κB decoy/pig/IR ↓/Improved 
Remodeling 
Morishita, R et. Al. 
[95] 
Nat Med/1997 NF-κB decoy/pig/IR ↓ Infarct Size 
 
None of these studies were designed to differentiate between inhibition of basal NF-κB 
activity versus inhibition of surge in activity associated with ischemic damage and cytokine 
release. With this background in mind, we hypothesized that blockade of cytokine mediated 
surge in NF-κB occurring via the canonical or classical pathway with the NBD peptide, in 
association with a PTD, would reduce infarct size in a mouse model of myocardial infarction.  
  
Table 2 - continued 
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2.0  PHAGE DISPLAY TO TARGET THE HEART 
It is clear from the preceding chapter that protein transduction technology is rapidly evolving and 
expanding in its applications, even though the exact mechanism of transduction remains 
incompletely elucidated, and is unlikely to be the same for the different PTDs. The one limitation 
these general PTDs have is their non-tissue specificity and ability to transduce a wide-range of 
cell types limiting therapeutic efficacy and potentially increasing toxicity. Biopanning or phage 
display would then be one useful technique to identify new PTD(s) which are tissue selective. 
We therefore undertook phage display to screen a large peptide-display M13 phage library with 
the goal of identifying peptide(s) able to transduce heart tissue selectively in vivo.    
2.1 PHAGE DISPLAY 
We screened a 12-mer M13 phage peptide display library (NEB, E8110S) for possible cardio-
selective peptide(s). We utilized a combinatorial in vitro single cycle followed by 3 in vivo 
biopanning cycles. The M13 phage display peptide library is based on a library of randomized 
dodecapeptides fused to a minor coat protein (pIII) of M13 phage. The displayed peptide (12-
mer) is expressed at the N-terminus of pIII, i.e., the first residue of the mature protein is the first 
randomized position. The peptide is followed by a short spacer (Gly-Gly-Gly-Ser) and then the 
wild-type pIII sequence. The library consists of approximately 2.7 x 109 electroporated 
 26 
sequences amplified once to yield approximately 100 copies of each sequence in 10 µl of the 
supplied phage. Hence in the library there will be few phage that are relevant with a far excess of 
irrelevant phage clones. To maximize selection of the relevant phage and minimize the large 
pool of non-specific phage, the first cycle was carried out in vitro on H9C2 cells, a rat 
cardiomyoblast cell line. These H9C2 cells have been characterized biochemically, 
morphologically as well as electrophysiologically [109]. Although these cells showed similar 
sugar residues on the surface coat as isolated rat cardiomyocytes, heart-specific morphological 
structures were not detected. These cells did show outwardly rectifying, transient K+ current as 
well as inward current through Ca2+ channels. Nevertheless, despite these differences, these 
cells have been widely utilized to study molecular pathways involved in ischemia-related 
apoptosis, hypertrophy as well as doxorubicin-mediated cardiac toxicity [110-114].  
Rat cardiomyoblast cell line, H9C2 cells, (ATCC, CRL-1446), were passaged at least for 
4 cycles. These cells were trypsinized and re-plated once they were ~70-80% confluent. After 4 
cycles they were grown again to ~70% confluence in a 6-well plate and incubated with 10ul, or 
~1011 pfu phage, for 6 hours, at 37˚C/5% CO2. At the end of the incubation period, the cells were 
washed 6 times with pre-warmed PBS, trypsinized with 0.25% Trypsin EDTA (GIBCO/BRL) 
for 5 minutes, and the cells pelleted by centrifugation for 5 minutes at a speed of 500rpms. The 
cells were lysed by a single freeze-thaw cycle, and the internalized phage tittered by infecting 
and growing in the provided E. coli bacteria. The recovered phage was amplified and re-tittered 
before use in mice for in vivo biopanning.  
For in vivo phage display, Balb/c, female, 10-12 week old mice were pre-treated with 
intra-peritoneal chloroquine at a dose of 20mg/Kg the day before and the day of phage injection. 
This is in contrast to prior reports of in vivo phage display, where short circulation times 
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(typically 10-60 minutes) were used, since the purpose was to target the vascular endothelium of 
various organs and tumors of interest. We utilized a prolonged incubation time as our aim was to 
go beyond the endothelium and target cardiomyocytes. Molenaar et. Al. had reported that the in 
vivo half-life of the M13 phage was 4.5 hours [115]. Since we aimed to recover actual, 
internalized phage and reduce contamination from the pool of circulating phage, we employed a 
much longer circulation time of 24 hours, equivalent to 5.5 half lives. In order to reduce 
intracellular breakdown of internalized phage, we pre-treated mice with Chloroquine the day 
before and day of phage injection (10mg/Kg, intraperitoneally), an agent shown to increase intra-
lysosomal pH in an attempt to increase chances of recovering internalized phage [116]. Phage 
were injected intravenously (retro-orbitally), mice euthanized 24 hours later, heart and kidneys 
dissected out, weighed and put through a collagenase digestion step. The isolated cells were 
lysed with a single freeze-thaw cycle, recovered phage tittered, amplified, re-tittered and injected 
again for a total of three in vivo phage display cycles. This experiment is represented 
schematically in the figure (Figure 7) below. The reagents utilized for these experiments, as well 
as the exact protocol details are presented in a step by step manner in Chapter 5, section 5.1: 
Protocol for Peptide Phage Display. 
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Euthanize, isolate myocytes, digest kidney, titrate recovered phage,
amplify phage, titrate amplified phage
Heart-target Kidney-control
Inject amplified phage i.v, circulate for 24hrs
+
Isolate cell, amplify 
and titrate Phage
3 Cycles
Pre-treat mouse with i.p Chloroquine (20mg/Kg) 
24hrs before and day of injection
H9C2 Cells Phage Library
 
Figure 7. Experimental design of the combinatorial in vitro and in vivo phage display. 
 
The recovered phage was normalized by gram of tissue digested and expressed as a ratio 
of heart to kidney and as an output to input ratio. The number of phage injected and recovered 
with each cycle is presented in Table 3 below.   
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Table 3. Number of phage injected and recovered from each cycle of phage display 
4.4360.00000025.55E+012.46E+029.98E+084
0.7670.00000351.55E+031.19E+033.42E+083
0.0230.00001332.04E+074.63E+053.48E+102
0.00005955.95E+061.00E+111
Heart/Kidney RatioOutput/Input Ratio
Output-
KidneyOutput-Heart
Input 
PhageRound
 
These results are represented graphically in the figure below (Figure 8) showing heart to 
kidney ratios (a.) and output to input ratios (b.). 
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b). Output to input ratio 
 
Figure 8. Recovered phage normalized to tissue weight and plotted as a ratio of heart to kidney (a) 
and output to input ratios (b). 
a). Heart to kidney ratio 
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Although the recovered number of phage and the output-to-input ratio decreased over 
subsequent biopanning rounds, the ratio of heart-to-kidney phage increased with an exponential 
increase from 3rd to the 4th cycle. The number of recovered phage decreasing over time is not 
surprising as the viability is likely to decrease with repeat freeze-thaw cycles and storage over 
time.  
After the 4th round of biopanning, 10 plaques were picked and the inserted sequences 
elucidated using the primers provided by New England Biolabs. Of these 10 plaques, 6 (60%) 
were identical and carried the sequence gcgccgtggcatctttcgtcgcagtattctcgtact. This translates into 
the following peptide sequence: Ala-Pro-Trp-His-Leu-Ser-Ser-Gln-Tyr-Ser-Arg-Thr 
(APWHLSSQYSRT). This peptide was termed Cardiac Targeting Peptide or CTP and  
synthesized by the peptide synthesis facility either conjugated to 6-carboxyfluoroscein,  
biotinylated at the N-terminus, or as a combination peptide carrying the nemo-binding domain 
peptide (NBD; sequence TALDWSWLQTE), which has been shown to inhibit activation of the 
inducible NF-kappa B Kinase (IKK) by binding to the regulatory subunit (Nemo) of IKK. 
Peptides were synthesized by Fmoc (N-(9-fluorenyl)methoxycarbonyl) solid phase 
synthesis, N-terminally biotinylated or labeled with 6-carboxyfluoroscein, purified by reversed-
phase high performance liquid chromatography to >90% purity on an acetonitrile/H2O-
trifluoroacetic acid gradient, and confirmed by electrospray ionization mass spectrometry 
(Peptide Synthesis Facility, University of Pittsburgh). Lyophilized peptides were reconstituted in 
PBS to a 1 mM stock solution concentration. In some peptide preparations, due to variability in 
the salt concentration, the peptide would not go completely into solution in PBS. In those 
instances, a 40mM stock solution was made in DMSO, with subsequent dilution to 1mM 
working solution by addition of PBS. Care was taken to use peptides suspended only in PBS or 
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dH2O for use in cell culture, and minimal DMSO used to re-suspend peptides for use in animal 
injections. All peptides were stored at -20˚C as a lyophilized powder, and re-constituted on the 
day of use.  
Calculating the physical properties of this peptide sequence CTP, using online tools, 
reveals a molecular weight of 1432.6, a net charge of 1.1 at pH of 7.0, an isoelectric point 
occurring at a pH of 9.35, with an average hydrophilicity index of -0.4 
(https://www.genscript.com/ssl-bin/site2/peptide_calculation.cgi).   
 
 
 MW:                       
1432.55 
PI:  
9.35 
 
Hydrophilicity Analysis: 
Peptide Charge Attribute 
APWHLSSQYSRT 2 Basic 
 
Note:  
• Red: acidic residues, like D E and C-terminal -COOH  
• Blue: basic residues, like R K H and N-terminal -NH2  
• Green: hydrophobic uncharged residues, like F I L M V W and Y  
• Black: other residues, like G A S T C N Q and P  
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• Z: Unrecognized codes are replaced of 'Z'. 
                       
Figure 9. Physical properties of Cardiac Targeting Peptide or CTP. 
 
In contrast to the earlier reported PTDs, like TAT or 16 amino acids from the third helix 
of Drosophila Antennapedia homeodomain (penetratin), which are rich in cationic, basic amino 
acids like arginine and lysine, this peptide sequence has only one arginine residue and is near-
neutral at physiological pH.    
2.2 In vitro Transduction Experiments: Confocal Studies 
In order to determine the ability of CTP to transduce cells in vitro, multiple different cell types, 
along with H9C2 cells were incubated with varying concentrations of 6-carboxyfluoroscein 
labeled CTP (CTP-6CF). A cardiomyoblast cell line (H9C2), a fibroblast cell line (NIH/3T3), a 
murine fibrosarcoma cell line (MCA205), a cervical cancer cell line (HeLa) and a human tubular 
cell line (HK-2), were passaged for a minimum of 3 cycles. After three cycles, cells were split 
and plated onto collagen-coated cover-slips (H9C2, HK-2 cells) or regular cover-slips (NIH/3T3, 
MCA205, HeLa cells) at a cell density of 2*105/well in a 6-well cell-culture plate. 24-hours after 
plating, the media was aspirated, cells washed with 1ml of pre-warmed (to 37˚C) Optimem once 
and left in 1ml of Optimem. Cells were then incubated at 37˚C/5%CO 2, with increasing 
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concentrations (50uM, 100uM and 200uM) of CTP-6CF (1mM working solution in PBS) for 30 
minutes, at the end of which cells were washed 6 times with pre-warmed PBS, fixed with 2% 
paraformaldehyde (see Chapter 5, Methods, Section 5.2.1 for “cell transduction experiments with 
CTP-6CF, and section 5.2.2 for details on making 8% paraformaldehyde stock solution) for 30 
minutes to which 1ul of a 1000X DRAQ5 (Molecular Probes, F1303), a nuclear stain, was 
added. After 30 minutes, PFA was aspirated, cells washed with pre-warmed PBS once, and the 
cover-slips mounted onto glass slides using gelvitol. After setting overnight, at 4˚C, light-
protected, cells were examined by confocal fluorescent microscopy. Below are confocal 
micrographs of various cell types showing preferential transduction of H9C2 cells over other cell 
types (Figure 10).  
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3T3 
      No Rx                     50uM                        100uM                       200uM 
 
 
HeLa 
HK-2 
H9C2 
MCA205 
Figure 10. Confocal micrographs of H9C2, 3T3, MCA205, HeLa and HK-2 cells incubated with 
increasing concentrations of CTP-6CF; Nuclei - blue (DRAQ5), CTP-6CF - green, 20x. Scale bars represent 
100uM. 
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These micrographs show uptake of CTP-6CF by H9C2 cells in a dose-dependent fashion 
with increasing uptake at higher concentrations. Uptake by 3T3, MCA205 and HeLa cells occurs 
to a much lesser extent and only at the highest end of the dose used (200uM, last panel). No 
uptake at all was seen at any of the tested doses by HK-2 cells, a human renal tubular cell line. 
Transduction experiments with H9C2 cell line were repeated with 200uM of CTP-6CF, 
incubated for 30 and 60 minutes and higher magnification confocal micrographs obtained. As 
shown in the figure below (Figure 11), CTP-6CF is intracellular with a punctuate distribution, 
similar to what has been reported for TAT, suggesting perhaps an endosomal localization of the 
peptide after internalization. 
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Figure 11. High magnification confocal micrographs of H9C2 cells incubated with CTP-6CF for 30 
(top row) and 60 minutes (bottom row). 
 
There has been concern voiced in literature following the reports on cationic cell 
penetrating peptides (CPP) that transduction with nuclear localization might be a result of a 
fixation artifacts [117-118]. TAT, a cationic, basic PTD, because of large number of arginine and 
lysine residues, has been shown to bind strongly to surface glycoproteins especially heparan 
H9C2 cells incubated with CTP-6CF for 30 mins: 40x and 60x  
 
H9C2 cells incubated with CTP-6CF for 60 mins: 40x and 60x  
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sulfate. This binding has been shown to be followed by endocytosis leading to internalization 
[119]. Thus the concern has been that transduction may simply be binding of positively charged 
peptides to heparan sulfate followed by endocytosis and any cytosolic or nuclear localization is a 
fixation artifact. To confirm that the above findings are actual transduction and not simply a 
fixation artifact, we followed H9C2 cells incubated with a random peptide sequence labeled with 
6CF (RAN-6CF), CTP-6CF or TAT-6CF with live imaging without any fixation protocols. The 
random peptide (ARPLEHGSDKAT) was the sequence of a phage picked from the original 
library that had not undergone any selection pressures of phage display. The figure below 
(Figure 12) presents the results after 60 minutes of incubation in which a DIC image is over-laid 
on the fluorescent image to give cell structural detail.  
RAN-6CF-200uM CTP-6CF-200uM
TAT-NBD-6CF-50uM
 
Figure 12. Live cell imaging of H9C2 cells incubated with RAN-6CF, CTP-6CF or TAT-6CF. 
 
 39 
These micrographs show intracellular and intranuclear fluorescence with both TAT-6CF 
and CTP-6CF, with no fluorescence uptake with RAN-6CF. To assess transduction without 
fixing cells or using fluorescent microscopy, we also did a functional assay to prove 
transduction, as detailed below. 
2.3 IN VITRO TRANSDUCTION: FUNCTIONAL ASSAY   
In order to assess transduction of H9C2 cells with CTP peptide, we used a reporter-Luciferase 
based cell assay, as described by Madge and May [120]. H9C2 cells were plated onto 96-well 
plates at a cell density of 2*104cells/well. Next day cells were transfected with a reporter plasmid 
expressing Luciferase under an NF-κB binding promoter site and a control Renilla expressing 
plasmid, using Lipofectamine. Twenty-four hours post-transfection, cells were pre-treated with 
increasing concentrations of the CTP-NBD (nemo-binding domain) peptide. NBD binds to the 
nemo binding site of IKKβ and to a lesser extent IKKα, preventing its association with NEMO or 
IKKγ, thus preventing activation of the IKK complex. This prevents phosphorylation of IκB and 
its subsequent degradation and release of NF-κB, which is not activated and remains cytosolic. 
Cells pre-treated with CTP-NBD were then challenged with TNFα, an NF-κB activator, and 
Luciferase activity measured in cell lysate. The methodological details of these set of 
experiments are provided in Chapter 5, Methods, section 5.3: Methodology for transfection of 
cells and inhibition of NF-κB activation. Figure 13 gives a schematic presentation of the 
experimental protocol.  
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Split/Plate H9C2 Cells
Transfect cells with NF-kappa 
B/Luciferase plasmid
Pre-treat cells with CTP-NBD 
for 30 mins
Stimulate with mTNFα
(10ng/ml) for 3 hrs
Lyse, collect cells, do Luciferase 
assay on the supernatant
  
Figure 13. Experimental protocol for the in vitro transduction experiments using Luciferase readout. 
     
All work was done in quadruplicate. The Luciferase readings were corrected for 
transfection efficiency differences using the Renilla readout. Differences across groups were 
compared using a two-tailed Student’s t-test. A p-value of <0.05 was considered statistically 
significant. Below are the results of experiments carried on H92 cells.   
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Figure 14. Inhibition of Luciferase activity by CTP-NBD in H9C2 cells. 
 
The exact same experiment with identical conditions was repeated in MCA205 cell line 
(Figure 15) as well as in HeLa cells (Figure 16). 
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Figure 15. Lack of inhibition of Luciferase activity by CTP-NBD in MCA205 cells. 
 
CTP-NBD was not able to inhibit TNFα mediated activation of NF-κB in MCA205 cells 
even at the highest tested dose of 400uM.  
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Figure 16. Relative lack of inhibition of Luciferase activity by CTP-NBD in HeLa cells. 
 
CTP-NBD failed to inhibit TNFα mediated NF-κB activation, except at the very highest 
dose used (400uM). This is consistent with the confocal micrograph data where transduction of 
HeLa cells by CTP-6CF occurred marginally at the highest dose used of 200uM (Figure 10). 
Following these inhibition of NF-κB activation studies, we performed cell viability 
studies to assess changes related to peptide treatment. The experiment was repeated with H9C2 
cells being doubly-transfected and pre-treated with CTP-NBD in increasing concentrations, 
followed by TNFα (10ng/ml) challenge for 3 hours. After this time period, the media was 
aspirated and replaced with MTT assay media to assess for cell viability. As shown below, 
inhibition of NF-κB with CTP-NBD led to decrease in cell viability in a CTP-NBD dose-
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dependent fashion. All treatment groups were done in quadruplicate. Error bars represent 1 
standard deviation (SD). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. H9C2 cell viability after transfection, treatment with CTP-NBD and subsequent TNF-
alpha treatment. 
 
This finding is consistent with reports in the literature that NF-κB inhibition increases 
apoptosis in H9C2 cells challenged with TNFα [121]. These results clearly demonstrate a 
biological effect of the NBD peptide that can only occur if the peptide was internalized by the 
PTD action of CTP. This decrease in cell viability did not occur with TNFα treatment or CTP-
NBD treatment alone as shown in Chapter 4, Figure 40.  
In summary, in this section we have shown transduction occurring preferentially of H9C2 
cells, a rat cardiomyoblast cell line, over a fibroblast, a fibrosarcoma, a cervical epithelial cancer 
cell line and human tubular kidney cell line using confocal fluorescent microscopy. We have also 
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demonstrated preferential transduction of H9C2 cell line over MCA205 cells or HeLa cells using 
a reporter plasmid carrying Luciferase expression under the control of an NF-κB binding 
promoter site. Next we will show transduction of heart tissue occurring in vivo with fluorescently 
labeled CTP.  
2.4 IN VIVO TRANSDUCTION STUDIES 
Our in vitro data showed preferential targeting of H9C2 cells over other, tested cell lines as 
assessed by confocal imaging, as well as a functional assay using Luciferase as a readout. This 
naturally led to the next question of whether preferential targeting of heart tissue will occur in 
vivo as well. The initial in vivo targeting studies were performed using CTP-6CF.  Female 
Balb/C mice were anesthetized using 2.5% Avertin, 12-15ul/gm of body weight, injected 
intraperitoneally. After adequate anesthetic levels were achieved, as assessed by lack of limb 
withdrawal to toe pinch or lack of a corneal reflex, mice were injected retro-orbitally with CTP-
6CF (25 mg/Kg) and euthanized 15 minutes later. The heart was dissected out, washed in PBS, 
placed in 2% paraformaldehyde (PFA) for 4 hours at room temperature (RT), followed by 30% 
sucrose, 4ºC, over night. Next day hearts were flash frozen in liquid nitrogen-chilled Isopentane 
and placed in -80ºC for later cryosectioning. After embedding in OCT, hearts were cryosectioned 
in the short-axis as 6uM thick sections and stained with DRAQ5, a nuclear stain. The sections 
were also stained for actin using phalloidin Alexa- 647 (Molecular Probes, A22287) and stained 
for laminin using a rabbit anti-laminin antibody followed by a goat anti-rabbit Cy3 (Jackson 
ImmunoResearch, 111-167-003) secondary antibody. Confocal microscopy was performed on 
these heart sections. The figure below (Figure 18) illustrates a section showing intracellular 
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localization of CTP-6CF, co-localizing with Actin. Laminin, which is present only on the surface 
of cells and hence has a ring-like appearance around myocytes, does not co-localize with CTP-
6CF, which has a distinctly different distribution pattern.  
 
                      
Figure 18. Transduction of mouse heart by intravenously injected CTP-6CF at 15 minutes. 
 
Female, Balb/C mice were injected retro-orbitally with PBS or CTP-6CF at a dose of 
25mg/Kg, euthanized at 15 minutes, hearts dissected and treated as outlined above. Five non-
overlapping, contiguous sections were taken from each heart for quantification of green 
fluorescence (CTP-6CF) expressed as a percentage of total area (blue; stained for actin). There 
were 3 mice in each group, and 5 sections quantified from each heart and averaged.  
The figure below (Figure 19) shows the mean amount of fluorescence in all sections. The 
error bars represent one standard error of the mean.  
CTP-6CF                                    Actin
Laminin Merged
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Figure 19. Quantification of fluorescence in mouse hearts (n=3 in each group). 
 
Next the biotinylated form of CTP (200uM) or PBS was incubated with Streptavidin-
Alexa488 conjugate (10ul of a 2mg/ml solution), at RT, light-protected, for 60 minutes, prior to 
injection intravenously (retro-orbitally) into Balb/C, female mice. An equivalent volume of 
PBS+streptavidin-alexa488 was injected as a negative control. Mice were euthanized at 30 
minutes, heart, liver, kidney, lung, skeletal muscle (hind-limb quadriceps), brain and spleen 
dissected out and treated as outlined above. The sections were stained with DRAQ5, cover-
slipped and confocal microscopy performed. For confocal microscopy, laser intensities/gains 
were set using negative control (PBS injected) heart tissue to minimize background fluorescence.  
Once laser intensity for the negative control hearts was set, it was kept constant across all 
subsequent imaging. Also serial scanning was performed to prevent “bleed-through” from one 
laser wavelength to another. Figure 20 below illustrates robust uptake of the peptide, as judged 
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by tissue fluorescence, with very little uptake by lung and kidney glomerular capillaries and none 
by skeletal muscle, brain, liver or spleen (data for spleen not shown).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
49 
 
 
 
 
 
 
  
 
 
Skeletal Muscle 
         
 
Liver 
Kidney 
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Figure 20. Transduction of heart tissue after intravenous injection with CTP-biotin-streptavidin-Alexa488 
complex. 
    CTP+SA488                                                PBS+SA488 
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Balb/C, female mice were also injected with the CTP-biotin-streptavidin-Alexa488 
conjugates and euthanized at different time points to study the biodistribution of this complex. 
The figure below, (Figure 21), shows transduction beginning at 15 minutes, localized to the sub-
epicardial region, with more diffuse uptake at 30 minutes and almost complete absence of 
fluorescence at 120 minutes.  
 
    
     
     
 
Figure 21. Biodistribution of CTP-biotin-streptavidin-Alexa488 complex after intravenous injection 
 
             Heart                                      Kidney                                      Liver 
15mins 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
30mins 
60mins 
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A random peptide (RAN; ARPLEHGSDKAT), picked from the original, unselected M13 phage 
library, was synthesized in a biotinylated form. Biotinylated RAN or CTP peptides were labeled 
with neutravidin-conjugated fluospheres (Molecular Probes, F8770) with an overnight incubation 
at 4ºC. These fluospheres are 40nm in diameter and fluoresce at an excitation wavelength of 605 
nm, allowing for in vivo bead tracking. Female Balb/C mice received intracardiac injections of 
fluospheres-labeled RAN peptide, CTP peptide or control PBS incubated with fluospheres alone. 
Mice were anesthetized with isoflurane delivered by the XGI-8 Gas Anesthesia System 
(Xenogen). Initial isoflurane concentration was set to 2.5% and was reduced to 1.5% once the 
animal was anesthetized. Mice were then imaged at 30, 60, 120, and 180 minutes post-injection 
with the IVIS Lumina (Caliper Life Sciences Inc.). The figure below (Figure 22) shows 
localization of fluorescence to the heart in mice injected with CTP+fluospheres, with rapid 
dissipation of fluorescence after injection with RAN+fluospheres or PBS+fluospheres. After 
three hours of imaging, these mice were euthanized, hearts dissected, processed as detailed 
above, cryosectioned, cross-stained with DRAQ5 and confocal microscopy performed.  
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Figure 22. In vivo, whole mouse imaging after intra-cardiac injection of CTP, RAN or PBS 
conjugated to fluorescent 40nm beads. 
     30mins 
 
  60mins 
 120mins 
180mins 
     
 
   Fluospheres Only          CTP+Fluospheres       RAN+Fluospheres      
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The confocal micrographs below (Figure 23) show a few myocytes with uptake of the 
fluospheres, actually much less than the whole mouse, in vivo imaging would suggest. Confocal 
microscopy did show fluorescent beads sticking to the endocardial region suggesting that these 
beads might only be able to stick to the surface and not be internalized as readily as CTP-6CF or 
CTP-biotin-streptavidin-alexa488 complexes. These beads are 40nm in size and the association 
with CTP-biotin may not necessarily be a one-to-one association leading to larger complex 
formations. This is indirectly supported by the observation that the solution injected was a highly 
viscous one and required a large-bore, 18G needle, precluding a peripheral tail-vein or retro-
orbital injection.    
 
Figure 23. Confocal micrographs of hearts injected with PBS+fluospheres, RAN+fluospheres or 
CTP+fluospheres. 
 
To demonstrate cell specificity of the CTP peptide in vivo, we undertook a second set of 
experiments. Balb/C, female mice were anesthetized with intra-peritoneal Avertin (2.5%, 10-
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15ul/gm of body weight), intubated with a 22G cannula using direct laryngoscopy and 
visualization of the vocal chords, and placed on a rodent ventilator (Harvard apparatus). The 
chest cavity was entered using a left, lateral ternotomy approach, and an anterior infarct 
produced by placing a suture through the anterior wall, 2mm inferior to the lowest dip of the left 
atrial appendage to blindly ligate the left anterior artery. Infarct was confirmed by the resulting 
pallor of the anterior wall and apex as well as wall motion abnormality produced in the region. 
The chest wall was closed in two layers, and the animal placed on a heating pad until awake. One 
week post-infarct, mice were re-anesthetized and injected intravenously with CTP-biotin-
Streptavidin-Alexa488 (SA488) complex or an equivalent volume of PBS with SA488 (10mg/Kg 
body weight). After 30 minutes of circulation time, mice were euthanized, hearts dissected out, 
washed, fixed, cryosectioned, cross-stained with DRAQ5, and confocal microscopy performed. 
Contiguous sections were also H&E stained to show the infarct area. Figure 24 below shows 
uptake of the fluorescently labeled CTP by normal heart tissue with exclusion of uptake from the 
infarcted, scarred myocardium (arrows). No uptake of PBS+SA488 alone was seen in any area of 
the heart. This experiment demonstrates in vivo cell specificity of our peptide, CTP, as it is taken 
up by normal myocardium and excluded from the scarred, infracted heart. The infarct is 
demonstrated in the H&E section by the lighter pink, thinned out area. 
 
 55 
 
 
Figure 24. Uptake of CTP-6CF preferentially by normal myocardium with exclusion from the infarct 
area. 
Our lab has shown that a homopolymer of lysine, 8K, is able to transduce multiple cell 
types effectively and consistently exceeding those of TAT and arginine homopolymers [16]. In 
order to compare transduction of heart tissue by CTP versus 8K, biotinylated form of these two 
peptides as well as a random peptide (RAN; mentioned above) were incubated with Streptavidin-
Alexa488 (SA488) for 60 minutes. Balb/C, female mice were anesthetized with intra-peritoneal 
Avertin and injected intravenously with CTP-SA488, 8K-SA488, or RAN-SA488 at a dose of 
10mg/Kg. At the end of a 30 minute circulation time, mice were euthanized, hearts and other 
organs dissected and processed as detailed above for cryosectioning and subsequent confocal 
microscopy. The figure below (Figure 25) shows transduction of heart tissue by CTP-SA488 in a 
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generalized manner at 30 minutes, with little uptake by kidney capillaries and none by the liver. 
In contrast 8K demonstrates robust transduction of kidney glomeruli and liver tissue, with little 
uptake by the heart. In contrast RAN-SA488 is not taken up by any of the tissues tested.  
 
     
     
     
     
 
Figure 25. Comparison of heart tissue transduction between CTP, 8K and RAN peptide. 
Heart 
Kidney 
   
 
Spleen 
  CTP+SA488                 8-Lysine+SA488               Random+SA488 
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2.5 HUMAN HEART TISSUE EXPERIMENTS 
Our work above has shown that in vivo phage display can be used to screen large phage display 
libraries for peptide(s) able to transduce cardiomyoblasts cell lines and heart tissue preferentially 
in vivo after a systemic, peripheral intravenous injection. The identification of such a peptide, 
CTP, raises many interesting and relevant questions. One key one would be whether this cardiac 
targeting is species specific or not. If such was the case, the utility of this peptide would be 
limited. In order to test whether CTP is able to transducer human heart tissue, we performed 
experiments ex vivo on explanted heart tissue.  
Heart transplantation is a destination, life-saving therapy for end-stage congestive heart 
failure. At the University of Pittsburgh Medical Center (UPMC) anywhere from 30 to 50 heart 
transplants are performed in a year. The Institutional Review Board has approved a protocol 
whereby patients awaiting heart transplant can consent to the use of explanted, diseased hearts 
for scientific experimentation with appropriate measures taken to protect patient identification 
and privacy. An extension of this protocol was sought where I could share tissue obtained at the 
time of heart transplant, in a blinded fashion, to run ex vivo incubation experiments with various 
fluorescently labeled peptides, including CTP.  
Human explanted hearts were obtained from the operating rooms of UPMC at the time of 
ongoing heart transplants. Heart tissue was dissected from the proximal part or the base of the 
heart to avoid the more scarred, infarcted, distal tissue. Small 1-2mm thick slices of heart tissue 
were taken and incubated with CTP-6CF (500ul of a 1mM solution) or PBS, for 30 and 60mins, 
at 37ºC / 5% CO2. At the end of the incubation period, the heart slices were washed in PBS 6 
times, fixed in 2% paraformaldehyde for 4 hrs at room temperature, followed by 30% sucrose 
overnight at 4ºC. Next day the tissue was frozen in liquid nitrogen-chilled isopentane and stored 
 58 
at -80ºC, for later cryosectioning, cross-staining with DRAQ5 and confocal microscopy. 
Confocal micrographs were obtained avoiding the edges because of the necessary damage 
associated with dissecting the heart tissue pieces. Confocal micrographs were taken 3-4 cell 
layers away from any edges. The figure below (Figure 26) demonstrates internalization of the 
peptide into heart myocytes. 
 
     
 
     
 
Figure 26. Transduction of human heart tissue ex vivo by CTP-6CF. 
         PBS       CTP-6CF-30mins 
            CTP-6CF – 60mins; 40x and 60x 
         50uM        
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    To investigate if this transduction was indeed peptide specific, and not secondary to 
increased membrane leakiness resulting from tissue being ischemic, we incubated thin, 1-2mm 
thick, heart slices, from a separate explanted heart, in only 6CF in PBS, CTP-6CF, RAN-6CF as 
well as 6CF labeled 6-Arginine, a known PTD. We also incubated heart slices with Evans blue 
dye (EBD) to assess for membrane leakiness. Evans blue dye fluoresces with an excitation 
wavelength of 620nm and emission wavelength of 680nm [122-123], making it possible to be 
imaged with fluorescent microscopy using the appropriate lasers for excitation. Heart tissue was 
incubated in 500ul of 1mM solution of all the peptides in PBS, for 30mins at 37˚C/5%CO 2. At 
the end of the incubation period, heart slices were rinsed thoroughly 6 times in 1ml of PBS and 
fixed in 2% paraformaldehyde for 4 hours, at room temperature, light-protected, followed by 
30% sucrose, overnight at 4˚C. Next day tissue was frozen in liquid nitrogen chilled Isopentane, 
embedded in OCT, cryosectioned, cross-stained with DRAQ5, mounted and confocal 
microscopy performed as detailed above. Confocal microscopy showed robust and diffuse uptake 
of both 6R-6CF and CTP-6CF, with occasional cells showing fluorescence in RAN-treated or 
6CF-treated hearts. Confocal microscopy of the EBD treated hearts did not show any 
fluorescence indicative of uptake which would have occurred had the membranes been 
significantly damaged by length of ischemia. The figure below (Figure 27) shows confocal 
micrographs of heart tissue treated with different peptides or controls.  
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Figure 27. Results of ex vivo human heart tissue experiment at 30 mins. 
 
The result of these ex vivo experiments demonstrates that CTP-6CF is indeed internalized 
by human myocytes as demonstrated by confocal microscopy and is not simply sticking to the 
outer surface. Moreover, this internalization is not seen with simply 6CF, the fluorescent 
chemical used to label all our synthesized peptides, and is not seen also with a random peptide. 
In contrast, 6R-6CF (homopolymer of 6 arginine amino acid residues), a known PTD, is indeed 
able to transducer these human myocytes ex vivo. Lastly, this internalization is not simply a 
result of increased membrane leakiness due to ischemia, as evidenced by lack of Evans blue dye 
uptake by the myocytes.  
 61 
2.6 CHAPTER SUMMARY 
In this chapter we have presented data demonstrating that a combinatorial approach of cell 
culture and in vivo biopanning or phage display can be utilized to identify a peptide, Cardiac 
Targeting Peptide (CTP), of transduction potential. This peptide is able to transduce a rat 
cardiomyoblast cell line, H9C2 cells, in vitro. This transduction is cell-specific and does not 
occur at all, or occurs at very low levels, in mouse fibroblast cell line, a fibrosarcoma cell line, 
human epithelial cancer cell line or human tubular endothelial cell line. We demonstrate that this 
peptide is not simply sticking to the surface and being internalized as a result of a fixation 
artifact with our functional Luciferase assay. In our assay Luciferase is expressed under the 
control of an NF-κB promoter that requires NF-κB activation to lead to expression of the protein. 
NF-κB is a cytoplasmic protein that acts as a transcription regulator and enters the nucleus after 
activation and joining of its sub-units, the commonest being hetero- or homo-dimers of p50 and 
p65 subunits. Our peptide is able to carry and internalize an 11-amino acid peptide, NBD (nemo-
binding domain), that inhibits this activation. In order to inhibit Luciferase expression, CTP must 
be internalized and escape the endosomal compartment and deliver NBD to the cytoplasm where 
NF-κB resides and prevent its subsequent activation.  
We have gone on to demonstrate that this transduction is indeed occurring in vivo as 
well, and is specific for the heart in mice. After a peripheral intravenous injection, CTP-6CF is 
seen to transducer mouse hearts robustly with little uptake by liver or spleen, with only a few 
lung and kidney capillaries showing fluorescence. This transduction peaks at 15mins for the 
smaller CTP-6CF, a 1790 Da molecule, but occurs at 30mins for the larger CTP-biotin-
Streptavidin-Alexa488 (CTP-SA488), an ~55kDa in size complex. The biodistribution studies 
revealed that transduction begins to occur as early as 15mins, peaks at 30mins and is almost gone 
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by 120mins. At the same time, the fluorescence seems to increase in kidney glomerular capillary 
cells, suggesting that this might be a route of excretion for the peptide or at least the fluorescent 
marker, 6CF, after peptide breakdown. 
Labeling the biotinylated form of our peptide CTP with red fluorescent streptavidin 
conjugated fluospheres made it possible to track this peptide in vivo using whole mouse imaging. 
CTP complexed with these 40nm fluospheres was injected intracardiac and mice followed by 
whole mouse imaging over multiple time points. The fluorescence was seen localized to the heart 
over 3 hours, as opposed to unconjugated beads or random peptide (RAN) conjugated to these 
beads. To further demonstrate the in vivo specificity of this peptide for normal heart tissue, mice 
underwent infarcts and a week post-infarct were injected with CTP-SA488 or PBS+SA488 
complex. Confocal microscopy revealed fluorescence in normal heart tissue with complete 
exclusion of fluorescence from the thinned-out, infarcted, scarred heart tissue, thus 
demonstrating cell specificity in vivo.  
In order to compare transduction efficiencies relating to the heart, mice were injected 
with fluorescently labeled CTP, 8K or RAN. Confocal microscopy showed transduction of the 
heart with CTP, with no significant heart transduction noted with 8K or RAN peptide, at similar 
doses and identical time-points studied. 
A peptide able to transduce heart tissue in vivo in mice alone would have limited 
applicability in terms of developing therapeutics or new imaging agents of ultimate clinical use. 
Therefore we sought to determine if CTP is able to transducer human cardiac myocytes ex vivo. 
As per a pre-existing IRB protocol, explanted heart tissue was collected from consenting patients 
undergoing heart transplants for end-stage congestive heart failure. A modification of this 
protocol allowed us to have access to this tissue in a blinded fashion. Thin, 1-2mm, slices of 
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freshly explanted human heart tissue were incubated with varying concentrations of CTP-6CF 
for 30 mins. Tissue was washed thoroughly in PBS and fixed and cryosectioned for later 
confocal microscopy. This revealed robust transduction of heart tissue, with minimal uptake of 
just 6CF, RAN, and no uptake of Evans blue dye (a marker used to assess membrane 
permeability). 6R, a known PTD used as a positive control in our experiments, was taken up by 
cardiomyocytes robustly as well.     
In conclusion, using a combinatorial approach of cell culture and in vivo phage display 
we have identified a peptide able to transducer rat cardiomyoblasts in a cell-specific manner in 
vitro, mouse heart tissue selectively in vivo and human heart tissue ex vivo.     
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3.0  MURINE INFARCT SIZE STUDIES USING NBD 
NF-κB was first identified as a transcription factor binding to the intronic enhancer of the Кappa 
light chain gene in B-cells over 20 years ago [44-45]. Since that initial description interest and 
research regarding this factor has been occurring at a blistering pace. As detailed in Section 1.6, 
NF-κB is unregulated in response to ischemia-induced surge in cytokines, primarily TNF-α and 
IL-6. Interestingly neutrophil depletion reduced this increase in TNF-α and IL-6, and reduced 
nuclear translocation of NF-κB [124]. In section 1.4, we detailed the role of IKKγ or NEMO and 
its interaction with the catalytic proteins IKKα and IKKβ. The specific domain responsible for 
the interaction of NEMO with NBD has been worked out and termed the NEMO-binding domain 
[52]. The same report also detailed out how a peptide, NBD peptide, complexed with 
Anntenapedia homeodomain, a PTD, was able to reduce TNF-α mediated NF-κB activation 
without diminishing the basal levels of NF-κB activity. In fact the basal NF-κB levels were 
somewhat increased in HeLa cells treated with the peptide (two-fold) as compared with 
untreated, control cells (40). Furthermore, NBD in association with varying PTDs (TAT or 
Anntenapedia) has been demonstrated to decrease inflammation associated pathologies 
(rheumatoid arthritis, inflammatory bowel disease) in animal models (see section 1.5 for more 
details). We therefore hypothesized that inhibiting NF-κB activation in a murine model of 
infarction by delivering NBD in association with a PTD at the time of ischemia would reduce 
infarct size.   
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3.1 GENERATION OF THE ANIMAL MODEL OF MYOCARDIAL INFARCTION 
In order to test the above hypothesis, an animal model of myocardial infarction was necessary. 
The following protocol was used and kept consistent from one set of experiments to another and 
between groups. Female, Balb/c, 10-20 week old mice were used for these set of studies. Female 
mice were chosen because of the ability to house 5/cage, as opposed to male mice (4/cage) and 
more importantly because female mice are able to tolerate cardiac insults better with lower post-
operative mortality [125]. Mice were anesthetized with intraperitoneal (i.p.) injection of 2.5% 
Avertin (a mixture of 15.5 ml tert-amyl alcohol to 25 grams of 2-2-2 Tribromoethanol - stock 
solution diluted to 2.5% concentration with PBS) at a dose of 15ul/gm of body weight. Adequate 
anesthetic level was assessed by lack of response to toe-pinch and lack of a gag reflex. Mice 
were intubated, using direct visualization of the vocal chords, with a 22G cannula and placed on 
a Harvard rodent ventilator apparatus. Tube placement was confirmed by symmetric expansion 
of the thoracic cavity. Mice were ventilated with ~0.1cc/breath tidal volume at a rate of 110 
breaths/minute. 
Following successful intubation/ventilation, the chest cavity was opened using a left 
lateral ternotomy approach. Care was taken not to extend the surgical incision cephalad to the 
level of the sternal head, as a large venous confluence is present in that region and cutting 
through them can lead to major, exsanguinating bleed. A self-retaining mouse retractor was 
placed inside the incision and the teeth opened to reveal the anterior surface of the heart. The 
pericardium was gently removed with blunt forceps. A suture, 6-0 prolene, blue, monofilament 
(Owens & Minor: #8714H) was placed along the lateral wall of the left ventricle (LV), ~2mm 
below the lowest dip of the left atrium and ligated with exactly 5 squarely-placed knots. Ischemia 
was confirmed by the resulting pallor of the myocardium and development of wall motion 
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abnormality. The muscle layer and skin were closed in two layers with running sutures with 8-0 
black, monofilament nylon suture (Owens& Minor: #2808G). The mice were extubated once 
spontaneous breathing was confirmed, and recovered on a heating pad. Post-operative pain was 
managed with subcutaneous injection of Ketoprofen, 5mg/Kg, on post-op day 0, 1 and 2 or with 
subcutaneous Buprenorphine, at a dose of 0.1mg/Kg body weight given once on the day of 
surgery and twice daily on post-op day 1 and 2. Mice also got one injection of subcutaneous 
Ampicillin, 100mg/Kg, after surgery for prophylaxis against post-surgical infection. Right after 
ligation and suture placement on the anterior surface of the heart to produce myocardial 
infarction, and before closing the chest wall, mice received i.p. peptides in different doses. The 
surgeon (myself) was always blinded to the treatment. Also surgeries were carried out in a 
rotational fashion so that any variation due to surgical technique was distributed equally over the 
treatment groups. 
Mice were euthanized on post-operative day 7. On day of euthanasia, mice were 
anesthetized, chest cavity opened, and 1cc of 1M KCl injected via the right ventricle (RV) in 
order to arrest the heart in diastole to prevent contraction band necrosis. This was followed by 
injecting, through the right ventricle, 5cc of Glyo-fixx (formalin-substitute), heart dissected out 
and placed in 15ml of Glyo-fixx, until tissue embedded for sectioning. After paraffin embedding, 
cross-sections of the heart were taken starting at the apex. The first section was taken once the 
LV cavity appeared, with second and third sections taken 10 microns apart and cephalad of the 
first section. The three sections were H&E stained, light microscopy photographs taken, and area 
of infarct in each section mapped out using computer software Metamorph and expressed as a 
percent of the whole heart. The infarct area from the three sections was averaged to give the final 
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infarct size for each mouse. All mouse protocols were approved by the University of Pittsburgh 
Institutional Animal Care and Use Committee (IACUC).  
  
3.2  INFARCT STUDIES USING 8K-NBD 
In view of the above background and after establishing the murine infarct model, we set out to 
test the following hypothesis. We hypothesized that suppression of NF-κB activation using the 
NBD peptide, with 8K as a delivery PTD, would reduce infarct size in a mouse model of 
myocardial infarction. Prior to the actual infarct study, we undertook whole mouse in vivo 
imaging to show that 8K-NBD is able to suppress NF-κB activation in response to LPS 
stimulation, a known activator of NF-κB.  
To demonstrate that 8K-NBD is indeed able to suppress NF-κB stimulation, we used 
Luciferase expressing transgenic mice with Luciferase expression controlled by an NF-κB 
promoter site. Mice were injected intraperitoneally (i.p.) with 8K-NBD (10mg/Kg) at time 0 and 
2 hrs with LPS injected immediately after the first 8K-NBD injection. Whole mouse in vivo 
imaging for Luciferase activity was performed at 30mins, 2hrs, 4hrs and 6hrs. As illustrated in 
the figure below, initial Luciferase signal was similar between the two groups of mice but at 4 
and 6hrs the signal increased in the LPS injected mice and remained stable/suppressed in the 8K-
NBD treated mice.  
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Figure 28. Inhibition of LPS induced Luciferase signal by 8K-NBD 
 
After these initial imaging experiments, we proceeded to the infarct studies. Mice 
underwent left artery ligation, as detailed above, and were treated with i.p. PBS, 8K-NBD or 8K-
mutant NBD (8K-mutNBD; KKKKKKKK-TTLDASALQME), at a dose of 5mg/Kg/injection, 
on post-op day 0 (immediately post-ligation) and post-op day 1 and day 2. Treatments were 
color-coded and administered in a rotational fashion. The surgeon was blinded to the treatment 
groups. Mice were euthanized on post-op day 7, heart dissected out and infarct size calculated, as 
detailed above in Section 3.1. A record of post-op mortality was kept. Also body weight and 
heart weight were recorded on day of euthanasia. There was an n=6 in each group. Figure 29 
below shows the post-op mortality in each of the three groups.  
6 hrs 
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Figure 29: Post-operative mortality by treatment group in the 8K-NBD study. 
 
 
However the heart-weight to body-weight ratios did not differ across the three groups as 
illustrated in Figure 30 below.  
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Figure 30. Heart weight to body weight ratios across the treatment groups in the 8K-NBD study. 
 
In contrast, and contrary to our expectations, the infarct size were significantly different 
across groups and worse in mice treated with 8K-mutNBD (Figure 31). Mice treated with 8K-
NBD had larger infarct sizes than PBS treated mice, though the difference showed a trend 
without reaching statistical significance.  
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Figure 31. Infarct size across different treatment groups in the 8K-NBD study.  
 
A cross-section from each heart was taken and apoptosis assessed by TUNEL staining. 
The nuclei were stained with Dapi, and the number of TUNEL positive nuclei expressed as a 
percentage of total nuclei in each field. The whole heart cross-section was taken into 
consideration by taking 5-6 contiguous, non-overlapping sections from each heart. The figure 
below demonstrates that the highest number of apoptotic nuclei occurred in 8K-NBD treated 
hearts, followed by 8K-mutNBD hearts with least number seen in the PBS treated heart sections.  
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Figure 32. Representative confocal micrographs of TUNEL staining in each treatment group in the 
8K-NBD study. 
 
The figure below (Figure 33) illustrates the TUNEL staining data in a quantitative 
manner.  
8K-NBD                                        8K-mutNBD 
 PBS 
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Figure 33. Quantification of TUNEL positive data in each treatment group in 8K-NBD study. 
 
From these set of experiments we conclude that although 8K-NBD is able to inhibit NF-
κB activation in response to LPS stimulation, this inhibition in a mouse infarct model appears to 
be detrimental and results in increased apoptosis occurring, as assessed by TUNEL staining, and 
a larger infarct size. Although 8K-mutNBD had lesser number of apoptotic nuclei, the infarct 
size was actually larger. This difference from the PBS treated group reached statistical 
significance. It is possible that although 8K-mutNBD has much reduced NF-κB inhibitory 
activity, it still has some level of inhibition which in an acute infarct model is detrimental. The 
apoptosis being less with a larger infarct size is difficult to explain and possibly within the realm 
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of biological variability as the infarct size in 8K-NBD treated and 8K-mutNBD treated mice was 
not statistically significant.  
3.3  INFARCT STUDIES USING CTP-NBD 
From the above section we conclude that although 8K-NBD is able to inhibit LPS-induced NF-
κB activity, such inhibition led to increased apoptosis and increase in infarct size. However the 
nature of these apoptotic nuclei, white blood cells/infiltrating cells versus cardiomyocytes was 
not clear. Data from this lab in a mouse model of inflammatory bowel disease in which treatment 
with 8K-NBD peptide was efficacious [18]. From our phage display experiments, we also noted 
that the transduction of heart tissue by 8K is quite inferior compared to CTP. We therefore 
hypothesized that the superior transduction ability of CTP would lead to better delivery of the 
NBD peptide to the heart tissue under ischemic stress and by inhibiting NF-κB activation above 
its basal level would be cardioprotective and reduce infarct size. 
 Female, Balb/c mice underwent left artery ligation as detailed in Section 3.1 above. Mice 
were treated either with PBS, CTP-NBD or 8K-NBD (both at a dose of 10mg/Kg body weight) 
on day of surgery, delivered i.p., right after ischemia was confirmed. Peptides were suspended in 
PBS. The surgeon was blinded to the treatment allocation and treatment was given in a rotational 
fashion. Post-operative pain control was achieved with I/M Ketoprofen (5mg/Kg) on day 0, 1 
and 2. Mice were euthanized on post-op day 7, heart dissected and processed for infarct size 
determination as detailed in Section 3.1 above. The post-operative mortality in each group is 
shown in the figure below (Figure 34). 
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Figure 34. Post-operative mortality by treatment group in the CTP-NBD study. 
 
The infarct size is shown in the figure below (Figure 35). As before, the infarct size was 
slightly more in the 8K-NBD treated group compared to the PBS treated group. However the 
CTP-NBD treated group showed a trend towards smaller infarct sizes.  
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Figure 35. Infarct size by treatment groups in the CTP-NBD study. 
 
Although this data was encouraging, the effect size was small and statistical analysis 
using this data showed that a prohibitively large sample size in each group would be needed to 
show significance. We decided to take an alternative approach. We hypothesized that the D-
isoform of CTP-NBD would be resistant to degradation, have a longer half-life and be able to 
inhibit NF-κB activation above its basal level much more effectively. To test this hypothesis, the 
D-isoform of CTP-NBD was synthesized in the University of Pittsburgh Peptide Synthesis 
Facility, with a fraction biotinylated at the C-terminus for conjugation with Streptavidin-
Alexa488 (SA488) for tracking studies.    
N=6 
N=8 
N=8 
 78 
Using the D-isoform of CTP-NBD (D-CTP-NBD) to reduce infarct studies raised a few 
questions. Since the mechanism of transduction with CTP is not known, would switching the L-
isoform with the D-isoform affect the transduction abilities adversely? Also would the D-isoform 
of NBD not be able to bind the IKK complex and therefore not inhibit NF-κB activation? To 
answer these questions the following studies were undertaken prior to repeating the mouse 
infarct studies with D-CTP-NBD.  
Two hundred microliters of a 1mM solution of D-CTP-NBD, biotinylated form, was 
incubated with 20ul of SA488 (2mg/ml stock solution) at room temperature (RT), light-protected 
for 60 minutes. 1ml of PBS was also incubated with 20ul of SA488 under identical incubation 
conditions. Female, Balb/c mice were anesthetized with i.p. Avertin and injected retro-orbitally 
with the D-CTP-NBD-SA488 complex at a dose of 10mg/Kg or PBS+SA488. Mice were then 
euthanized at 30 minutes (time to peak transduction with L-isoform CTP) or 120 minutes, hearts 
taken, fixed in 2% paraformaldehyde at RT for 4 hrs, overnight 30% Sucrose at 4˚C, frozen in 
liquid N2 chilled Isopentane and cryosectioned. PBS injected mice were euthanized at only 30 
minutes. After cross-staining with DRAQ5, a nuclear stain, confocal microscopy was performed 
to look for fluorescence. Confocal microscopy showed robust uptake of D-CTP-NBD-SA488 
complex albeit at a slower rate than L-isoform CTP. There was beginning of transduction noted 
at the edges with deeper tissue showing transduction at 120 minutes, as shown in figure below 
(Figure 36).  
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Figure 36. Transduction of the mouse heart by the D-CTP-NBD-SA488 complex. 
 
To investigate if D-CTP-NBD retains its ability to inhibit NF-κB activation in response to 
TNFα stimulation, the cell culture Luciferase studies were repeated. H9C2 cells were plated onto 
96-well plates and double transfected with a plasmid carrying Luciferase under an NF-κB 
promoter site as well as a Renilla expressing control plasmid. 24 hours post transfection, cells 
were pre-treated with increasing concentrations of the D-CTP-NBD peptide and 30 minutes later 
challenged with TNFα for 3 hours. After three hours, cells were washed, trypsinized, lysed and 
Luciferase and Renilla activity quantified in a luminometer. All work was done in quadruplicate. 
     PBS+SA488                                  D-CTP-NBD-SA488 – 30mins 
D-CTP-NBD – 120mins 
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The figure below (Figure 37) shows that D-CTP-NBD is a less potent inhibitor of NF-κB 
activation with any appreciable inhibition occurring only at the highest tested dose (400uM).  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
 
Figure 37. Inhibition of NF-κB activation by the D-isoform of CTP-NBD. 
                                                                                                                                                                                                                                                  
Although inhibition of NF-κB did occur, it was seen only at the highest tested dose. 
Given that the transduction process was slowed down as seen in the in vivo imaging mouse study 
(Figure 36), we hypothesized that perhaps 30 mins of incubation/lead time was not adequate with 
D-CTP-NBD. However pre-incubating with 60 mins or 120 mins produced identical results with 
~40% inhibition seen, only with the highest dose (400uM), as compared with the TNFα-
stimulated cells (results not shown). In spite of these findings, we choose to test the peptide in a 
mouse infarct model, hypothesizing that although inhibition occurs only at the highest tested 
dose, this dose might be achievable given the robust transduction seen at 120 mins as well as 
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probable accumulation of D-CTP-NBD inside cardiomyocytes to a high enough concentration 
given it’s resistance to intracellular degradation.  
Mice underwent left artery ligation, as detailed above. Only one dose of D-CTP-NBD or 
PBS was administered at time of surgery (5mg/Kg, i.p.), and mice were euthanized on post-op 
day 7. The surgeon was blinded to the treatment allocation and post-op pain control was 
achieved with s.q. Buprenorphine (0.1mg/Kg body weight). As shown in the figure below, 
infarct size did not differ between the two groups.   
 
                      
 
 
 
 
 
 
 
 
 
 
Figure 38. Infarct sizes in the two treatment groups. 
 
In addition, if infarct sizes of less than 10% were excluded, the mean infarct size in the 
two groups was nearly identical leading us to conclude that treatment with D-CTP-NBD did not 
have any significant effect on infarct size. Probably the most likely explanation for this lack of 
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an effect, despite promising earlier data, is the lack of adequate inhibition of NF-κB activation by 
the D-isoform of NBD. Although inhibition in cell culture studies, utilizing H9C2 cells, did 
occur, it was apparent only at the highest dose tested (400uM). This level might not have been 
achievable at the dose of 10mg/Kg body weight in vivo to produce a biological effect. In 
addition, later studies of NF-κB inhibition [3, 105, and 106] have shown that infarct sizes are 
similar in control and NF-κB inhibited mice, but remodeling is favorably affected in the latter 
group. In our studies, mice were euthanized at post-op day 7, which would be too early to see 
differences in post-infarct modeling or differences in left ventricular function.   
In summary, these set of experiments demonstrated lack of a significant biologically 
favorable effect of inhibiting NF-κB, utilizing 8K-NBD. In fact a trend towards worsening of 
infarct size was apparent in multiple studies suggesting that the initial surge of NF-κB activation 
that follows ischemic myocardium may have a protective role. Also 8K, as a protein transduction 
domain, may be targeting cell types different than the actual myocytes and may be targeting 
more of the inflammatory infiltrating cells. Inhibiting NF-κB in neutrophils, utilizing NBD, has 
been shown to increase apoptosis of these cells in response to LPS stimulation [17]. Increasing 
neutrophil apoptosis, at the earliest stage of the inflammatory response to myocardial ischemia, 
may well be detrimental. Lack of a response of any kind to D-CTP-NBD in the subsequent 
studies was likely not a failure of transduction with the D-CTP isoform but rather a lack of 
adequate NF-κB inhibition by the D-isoform of NBD.   
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      4.0  SUMMARY, IMPLICATION OF OUR FINDINGS AND FUTURE DIRECTIONS 
4.1 SUMMARY OF OUR FINDINGS 
In this body of work we have utilized a combinatorial cell culture and in vivo phage display to 
identify a peptide that targets rat cardiomyoblast cells (H9C2 cells) in vitro and mouse cardiac 
tissue in vivo. This peptide, which we termed cardiac targeting peptide, or CTP, is able to deliver 
a cargo peptide, NBD or nemo-binding domain to H9C2 cells in culture, and deliver 
Streptavidin-Alexa488 complex to mouse cardiac tissue in vivo. The method of phage display 
was first demonstrated by Smith [32], and in vivo phage display by Pasquallini and colleagues 
[37]. Since the initial description of in vivo phage display, studies have been carried out to target 
vasculature ligands of different organs demonstrating that the endothelial lining of various 
organs is far from being homogenous. Such heterogeneity of vasculature ligands has been 
demonstrated for different normal organs as well as diverse disease states like tumor vasculature 
[37] and atherosclerotic plaques [126]. Most of these studies have focused on targeting vascular 
ligands. In contrast, our work was meant to target more the cardiomyocytes in vivo, going 
beyond the vasculature. We aimed to identify a peptide that would be able to traverse the 
endothelial barrier of the heart, traverse the interstitium, bind and be internalized by 
cardiomyocytes in vivo. Such a unique peptide would have to be teased out of a large library, 
with high background of contaminating, non-specific phage, especially as the heart is an 
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extremely vascular organ and would be rich in the circulating blood pool of phage. We optimized 
our chances by pre-enriching the phage pool with a single cell culture cycle on H9C2 cells before 
undertaking the in vivo cycles of phage display. The problem of contaminating phage in the 
blood pool was minimized with prolonged circulation times to allow for clearance of phage from 
the circulation and maximize the chances that phage recovered from the heart would be the 
relevant, internalized one. Further, to maximize our chances of recovering phage, mice were pre-
treated with chloroquine to minimize degradation of internalized phage by preventing 
acidification of the intracellular lysosomal compartment. Using these methodological changes, 
we were able to identify CTP and show that it is not simply associated with vascular or 
cardiomyocytes surface, but able to be internalized. 
As a separate, though related, piece of work we went on to establish a mouse model of 
myocardial infarction and test nemo-binding domain (NBD) peptide’s ability to reduce infarct 
size in association with 8K, a known PTD from this lab. Later as the identity and transduction 
ability of CTP was established, we utilized CTP-NBD to assess if this peptide was able to reduce 
infarct size in vivo. As detailed in Chapter 3, though 8K-NBD was able to inhibit surge of NF-
κB activation in response to LPS, it actually increased infarct size in our model. Although CTP-
NBD was able to somewhat reduce infarct size in earlier studies, the effect size was modest and 
would require large sample sizes to reach statistical significance. To prolong the action duration 
of CTP-NBD, we utilized the D-isoform of all the amino acids constituting the peptide. Although 
transduction ability of CTP was retained, it slowed down considerably and NBD was not able to 
inhibit NF-κB activation, except at the highest concentration tested, and likely non-physiological 
doses (400uM), in vitro. Such high concentrations were likely not achieved, in vivo, and may 
explain the lack of effect noted with D-CTP-NBD.         
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4.2 IMPLICATIONS AND FUTURE DIRECTIONS 
A protein transduction domain able to transduce heart tissue specifically in vivo would open up 
avenues for better imaging, as well as a delivery agent for potential therapeutics. We believe that 
this is what we have achieved with identification of CTP. However this work has opened many 
interesting questions. Foremost is the mode of transduction pathway that this peptide utilizes. 
From the above discussion (Section 4.1), it is clear that this mode of delivery is likely to be 
complex and has to overcome many barriers to actual transduction of the cardiomyocytes in vivo. 
There has been immense interest in the mode of transduction utilized by PTDs in general with 
greatest body of work gathered on TAT. This work has revealed that TAT, being a highly 
cationic peptide, binds to heparan sulfate groups on cell surface followed by internalization, 
likely by a macropinocytotic mechanism [127-128]. This is unlikely to be the mode of uptake by 
CTP, as it is neither arginine-rich, nor is it cationic, with an isoelectric pH of 9.35 and 
hydrophilicity index of -0.4. Indeed our lab has started performing preliminary experiments to 
tease out the mechanism of transduction. In one set of preliminary experiments, H9C2 cells were 
incubated with 200uM of CTP-SA488 complex at 37˚C or 4˚C for 30 mins. After equal number 
of washes, cells were fixed, counter-stained with DRAQ5 and confocal microscopy performed. 
The figure below (Figure 39) shows transduction occurring at 37˚C with minimal to no 
transduction seen at 4˚C, implying that transduction is an active, energy -dependent process, and 
not a simple diffusion of a peptide across the lipid cell membrane.      
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Figure 39. Temperature dependency of CTP's transduction ability. 
 
Moreover viability studies were performed in H9C2 cells after incubating with increasing 
concentrations of CTP-NBD for 30 minutes at 37˚ C/5% CO2. After the incubation period, cells 
were washed and viability assessed using a standard MTT assay. As shown in the graph below, 
no significant change in viability was noted with CTP-NBD, even at the highest end of the tested 
concentration. Therefore transduction is not likely simple uptake of CTP by compromised cells. 
 
PBS
SA-488-37ºC
CTP+SA-488-37ºC
SA-488-4ºC
CTP+SA-488-4ºC
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Figure 40. H9C2 cell viability after incubating with increasing concentrations of CTP-NBD. 
 
Interestingly a group of investigators have identified the identical CTP sequence, via 
phage display, as binding preferentially to bone-like mineral and hydroxyapatite material [129-
130]. Although this work involved in vitro phage display against immobilized hydroxyapatite 
discs, the fact that such a display led to the exact same sequence as CTP being identified 
suggests that this peptide may be able to bind to cardiac interstitium. However for this to happen, 
the heart endothelial barrier must be traversed first. Zhang and colleagues profiled heart 
vasculature endothelium using in vivo phage display as well as bacterial two-hybridization 
scheme, and identified a number of peptides able to bind anywhere from ~15 fold to 310 fold 
greater avidity to heart endothelial cells [39]. None of these identified peptides bear any 
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homology to the CTP sequence. Moreover, the high magnification confocal micrographs of 
H9C2 cells (Figure 11) showing punctate intracellular, cytoplasmic fluorescence, along with 4˚C 
transduction experiments reported above, suggest that transduction with CTP is an energy 
dependent process involving binding of CTP to a ligand followed by endocytosis. The ligand 
CTP is targeting remains to be identified. The next step would then be to confirm the 
cytoplasmic substructure that CTP ends up in, using higher magnification confocal micrographs 
of H9C2 cells along with endocytic markers. The exact ligand CTP is targeting can be identified 
using a bacterial two-hybridization scheme similar to that reported by Zhang et. Al. [39]. Such 
mechanistic insights would be critical to assess CTP’s ability to deliver cargoes, in addition to 
the size limitations, to the heart. It is likely that the size and/or nature of the cargo could very 
well diminish CTP’s transduction ability.  
I see the potential clinical utility of CTP as not only a therapeutic delivery vehicle, which 
of in itself would be of great benefit, but also as improving our diagnostic abilities. Recently 
attention has focused on patient exposure to medically necessary ionizing radiation [131] which 
can be considerable over time and have a cumulative effect. As was also pointed out in this study 
[131], a major portion of the ionizing radiation exposure is from nuclear studies of which cardiac 
nuclear studies constitute a significant percent. When injecting patients with radio-isotopes like 
Thallium or Technetium, the majority of the radiation is taken up by the liver and gut regions. 
Not only does that necessitate injecting a higher amount to target the heart, but also, not 
infrequently, degrades the cardiac image quality. The inferior wall of the left ventricle is 
particularly difficult to assess because of its proximity to the diaphragm as well as high 
background gut activity just underneath the diaphragm. Labeling CTP with a radioisotope, like 
technetium, has the potential to decrease total radiation exposure and actually increase image 
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quality by directing all of the radiation to the heart. The proof of principal and ability to label 
peptides with radio-isotopes and use for imaging has already been reported [132] and therefore is 
feasible.  
Another interesting potential application of CTP would be to express it on coat-protein of 
adenoviral or adeno-associated virus to target viral particles to the heart. In this arena, we have 
started work with AAV viral vectors in collaboration with Dr. Nakai’s lab. This lab has produced 
a gutted out version of the AAV9 vector, termed the AAV1.9-3 vector, which lack heparan 
binding sites. This viral vector has prolonged half-life in blood and limited transduction ability. 
This virus can be retargeted by placing an RGD motif back in its coat protein. Preliminary 
experiments assessing ability of AAV2, AAV1.9-3, AAV1.9-3RGD and AAV1.9-3-CTP (with 
CTP sequence placed at position 587 of the viral coat protein) to transduce H9C2 cells appear 
promising. The figure below demonstrates the ability to de-target and retarget AAV9 vector. 
Addition of CTP to the de-targeted virus appears to be cautiously promising, though much work 
remains to be done.  
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Figure 41. H9C2 cells transfected with different AAV viral vectors expressing EGFP. 
 
Two major issues are the inability to package larger marker genes like LacZ into these 
modified viruses, and the sharp drop in titers that occurs with modification of the coat protein 
making large scale production difficult, if not impossible. These problems are in the process of 
being addressed and will hopefully help in making AAV vectors more cardiac specific.              
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5.0  METHODS 
This chapter will outline in depth the step by step methods followed to do in vitro and in vivo 
phage display. It will be followed by details of the cell transfection protocols as well as the 
Luciferase read-out assay utilized to document TNFα mediated NF-κB activation as well as 
inhibition of it by CTP-NBD fusion peptide. Later in the chapter, details will be provided of the 
mouse infarct model, euthanasia protocol as well as determination of infarct size on H&E 
histology slides. 
5.1      PROTOCOL FOR PEPTIDE PHAGE DISPLAY 
The protocol describes below the steps leading to a pre-screening cycle being performed in vitro 
on rat cardiomyoblast cell line, or H9C2 cells, utilizing a commercially available (New England 
Biolabs, cat#E8110S) M13, twelve amino acid peptide phage display library. After the first cycle 
in vitro, the subsequent three cycles were performed in vivo, as detailed below. 
 The protocol detailed below, utilizing peptide phage display to identify internalizing 
phage and the peptide sequence leading to internalization, is modified to target heart tissue in 
vivo. The process is complicated by the heterogeneity and complexity of the tissue being 
targeted, the sequestration of injected phage by organs of the reticuloendothelial system, largely 
the liver and spleen, and a large pool of contaminating, non-specific circulating phage. In 
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addition, the rigorous conditions that the phage displaying peptides are put through leads to loss 
of infective phage over subsequent cycles. Here we provide details of the protocol used to 
identify peptides transducing the heart with kidney being used as control tissue.  
 
5.1.1 Materials  
Cell Culture: 
1. Dulbecco’s Modified Eagle’s Medium (DMEM; GIBCO/BRL)  
2. Heat-inactivated fetal bovine serum (FBS; GIBCO/BRL) 
3. Pen Strep stock solution (GIBCO; 15140) 
4. Hepes buffer solution 1M (GIBCO; 15630) 
5. Rat Cardiomyoblast Cell Line (H9C2 Cells) Media. Make the H9C2 cell media by adding 
50ml of heat-inactivated FBS, 5ml of Hepes, and 5ml of Pen-Strep to 500ml of DMEM. 
Filter the mixture and store at 4˚ C.  
6. Solution of trypsin (0.25%) and ethylenediamine tetraacetic acid (EDTA-1mM; GIBCO) 
Phage Display  
1. M13 12-mer peptide phage display library containing: 
a. Phage display peptide library, 100ul, ~1x1013 pfu/ml, in TBS with 50% glycerol 
b. -96 gIII sequencing primer5´- HOCCC TCA TAG TTA GCG TAA CG –3´, 100 
pmol, 1 pmol/μl 
c. -28 gIII sequencing primer5´- HOGTA TGG GAT TTT GCT AAA CAA C –3´, 
100 pmol, 1 pmol/μl 
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d. E. coli ER2738. Host strain supplied as 50% glycerol culture; not competent. 
Store at –70°C. 
2. LB Medium: 10 g Bacto-Tryptone, 5 g yeast extract, 5 g NaCl in 1 liter of H2O. 
Autoclave, store at 4˚ C.  
3. IPTG/Xgal Stock Solution: Mix 1.25 g IPTG (isopropyl-β-D-thiogalactoside) and 1 g 
Xgal (5-Bromo-4-chloro-3-indolyl-β-D-galactoside) in 25 ml DMF (dimethyl 
formamide).Solution should be stored at –20°C. 
4. LB/IPTG/Xgal Plates: 1 liter LB medium + 15 g/l agar. Autoclave, cool to < 70°C, add 1 
ml IPTG/Xgal Stock per liter and pour.Store plates at 4°C in the dark. 
5. Agar Top: 10gm Bacto-Tryptone, 5gm yeast extract, 5gm NaCl, 7gm Bacto-Agar in 1 
liter of deiodized H2O. Autoclave, dispense into 50ml aliquots. Store at room temperature 
(will be solid).  
6. Tetracycline Stock Solution: 20mg/ml of tetracycline powder in a 1:1 Ethanol:Water. 
Store at -20˚C, light-protected. Vortex before use.  
7. LB+Tetracycline Media: To 1 liter of H2O add 10 g Bacto-Tryptone, 5 g yeast extract, 
and 5 g NaCl. Autoclave, and allow to cool down to <70˚C or until lukewarm to touch. 
Add 1ml of Tetracycline stock solution, mix and store at 4˚C, ligh t-protected, until ready 
for use. Do not use if color turns from yellow to brown or black.  
8. LB/Tetracycline Plates: Add 15gm of Agar to a liter of LB medium. Autoclave and allow 
to cool to <70˚ C, add 1ml of tetracycline stock solution, pour into plates and  allow to 
solidify. Store plates at 4˚C, light -protected. Do not use plates if they turn brown or 
black. 
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9. TBS: 50 mM Tris-HCl (pH 7.5), 150 mM NaCl. Autoclave and store at room tempera-
ture. 
10. PEG/NaCl: 20% (w/v) polyethylene glycol–8000, 2.5 M NaCl. Autoclave, mix well to 
combine separated layers while still warm. Store at room temperature. 
11. Iodide Buffer: 10 mM Tris-HCl (pH 8.0), 1 mM EDTA, 4 M sodium iodide (NaI).Store 
at room temperature in the dark. Discard if color is evident. 
Biopanning in mice 
1. 8 to 12 week old albino, male or female mice (Balb/c or FVB; Jackson Labs) 
2. 0.5ml Insulin syringes 
3. Sterile phosphate buffered saline (PBS; GIBCO) 
4. Avertin stock solution: Avertin (2, 2, 2-Tribromoethanol; Sigma-Aldrich) is mixed with 
15. 5 ml tert-Amyl Alcohol (2-methyl-2-butanol; Fisher) for ~12 hours in a dark bottle at 
room temperature. Allow the mixture to go completely into solution, sterile filter and 
store at 4˚C, light protected. On the day of use, mix 200ul of this stock solution with 
10ml of PBS, sterile filter and wrap in foil before use. This will be the 2% Avertin 
working solution.  
5. HBSS (Cellgro) 
6. 10% Glucose. Dissolve 10gm of glucose in 100ml of deionized H2O, sterile filter in a 
hood and store for later use 
7. Heparin 1000U/ml (Lyphomed) 
8. Collagenase II (50mg/ml; Worthington) 
9. DNAse I (20mg/ml; Roche) 
10. Dulbecco’s Modified Eagle’s Medium 50:50/F12 (Cellgro)  
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11. Heat-inactivated fetal bovine serum (FBS; GIBCO/BRL) 
12. Gentamycin 50mg/ml (1000x; GIBCO) 
13. 75μM cell filters 
2. Solution of trypsin (0.25%) and ethylenediamine tetraacetic acid (EDTA-1mM; GIBCO) 
15. HBSS-G: To 90 ml of HBSS, add 10 ml of 10% glucose solution.  
16. HBSS-G-Heparin: To 50ml of HBSS-G, add 500ul of Heparin (1000U/ml stock 
solution). Make fresh on the day of use. 
17. Digestion Enzyme: To 39ml of HBSS-G add 40ul of DNAse I and 1.2 ml of Collagenase II. 
Make fresh on the day of use.  
18. Plating medium: To 90 ml of DMEM 50:50/F12 add 10ml of the heat inactivated FBS and 
100ul of Gentamycin stock solution. 
19. 0.75% collagenase II: Add 75mg of collagenase II to 10ml of PBS. Make fresh on the day of 
use. 
20. DMEM 50:50/F12/25% FBS: add 7.5ml DMEM/F12 to 2.5ml FBS. Will need 10 cc for each 
heart.      
5.1.2 Methods 
Peptide Phage Display 
a. Passage the rat cardiomyoblast cell line, H9C2 cells, for a minimum of 3 passages (after 
thawing from -180˚C). Cells should be passaged once they are ~70% confluent. Do not 
allow to grow to complete confluency as they will begin to differentiate. 
b. After the third passage, trypsinized cells with Trypsin/EDTA and plate in a 6-well plate 
at a cell density of 2*105 cells/well. Twenty-four hours post-plating, aspirate and replace 
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with pre-warmed media, and add 10ul of the M13 peptide phage library (~1011 phage)to 
the media. Return cells to incubator for 6 hours.  
c. After the incubation period, wash cell extensively (at least 6x) with pre-warmed PBS, 
trypsinized cells, and centrifuge to collect cell pellet. Wash the cell pellet 1-2 times more 
with media. Aspirate the supernatant media above the cell pellet but not completely. Cell 
pellet may be stored at -80˚C for later lysis and phage titration. 
d. Release internalized phage by subjecting the cell pellet to one freeze-thaw cycle by 
bringing the cell pellet from -80˚C to either room temperature, or by placing in a 37˚ C 
water-bath. Pellet out the cell debris and use the supernatant for phage titration as 
detailed below. 
Phage Titration 
a. Inoculate 100ml LB+tetracycline media in a round-bottomed flask with 10ul of E. coli, 
provided with the phage display library. Grow overnight at 37˚C with gentle shaking (225 
rpm). This will be the starter culture. 
b. Inoculate another 100ml of LB+tetracycline media with 1-2 drops of the starter culture. 
Incubate at 37˚C for 1hr with gentle shaking.  
c. Melt agarose top in a microwave until liquid. Vortex to make sure it is homogenous. 
Dispense 3ml into 6 sterile culture tubes. Place the 6 culture tubes in a water-bath with 
temperature set to 45˚ C and maintain at this temperature until ready for use.  
d. To carry out infection, add 20 μl of cell extract (from Step 2.1d.) to 200ul of E. coli 
culture (from Step 2.2b.), vortex quickly, and incubate at room temperature for 1–5 
minutes. This will be the 1X100 dilution. Take 20ul of this and add to another 200ul of 
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the starter culture (1X101) and so on until you have 1X106 dilutions. Use a new tip for 
each serial dilution.  
e. Transfer 200ul of each of these to the culture tubes containing 3ml of the melted agar top 
at 45˚C, one infection at a time (from step 2.2d.),  vortex briefly, and immediately pour 
culture onto a pre-warmed LB+Tetracycline plate or IPTG/X-gal plate (labeled 1x100-----
----1x106). Pre-warm, for at least one hour, one LB/IPTG/Xgal plate per expected dilu-
tion at 37°C until ready for use. Gently tilt and rotate plate to spread top agar evenly. 
f. Allow the plates to cool for 5 minutes, invert, and incubate overnight at 37°C. Place in 
37˚C, light-protected (for either type of plates) for overnight growth. 
g. Next day count either the clear plaques in the case of LB+Tetracycline plates, or blue 
plaques in the case of Xgal plates. Some plates will have too numerous to count plaques 
and some might have too few. Count the ones with 10-200 plaques, multiply by the 
dilution factor and that will provide the number of phage per 20ul of the cell lysate. The 
total number of phage can be calculated by multiplying this number by the total lysate 
cell supernatant volume (in ul) divided by 20.  
 
Total No of Phage = Number of plaques in a plate * Dilution factor of the plate * 
total cell lysate volume/20 
 
Phage Amplification 
a. Inoculate 100ml LB+tetracycline media in a round-bottomed flask with 10ul of E. coli, 
provided with the phage display library. Grow overnight at 37˚C with gentle shaking (225 
rpm). This will be the starter culture. 
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b. Inoculate another 100ml of LB+tetracycline media with 1-2 drops of the starter culture. 
Incubate at 37˚C for 1hr with gentle shaking.  
c. Take 32ml of this culture and add 1-1.5ml of the cell lysate (from 2d. above) to it and 
grow for 4 hours at 37˚ C with gentle shaking (225 r pm). 
d. Spin down at 10,000rpms at 4˚ C for 20minutes.  
e. Discard the pellet. Take the 30ml of the supernatant and add 6ml of PEG/NaCl and keep 
at 4˚C overnight. 
f.  Next day spin the tube at 12,000rpm for 20minutes at 4˚C.  
g. Discard the supernatant and dissolve the pellet in 1cc of TBS (in the hood). Transfer to 
eppendorf tube and add 200ul of PEG/NaCl (all in the hood). Place on ice for 1 hour. 
h. Spin the tube in cold room at 14,000rpm for 5 minutes. 
i. Discard the supernatant. Resuspend the pellet in 200ul of TBS. This is your amplified 
phage. Titer this amplified phage using the protocol detailed in Methods-2.3. This will be 
the amplified and tittered phage used for next cycle of phage display, which will after this 
initial pre-screen, will be in vivo.  
 
In vivo Peptide Phage Display  
Weigh the mouse on a small animal scale and anesthetize using 12ul/gm of tissue weight of 2% 
Avertin solution administered intraperitoneally. Mouse will be anesthetized in 2-5 minutes. 
Inject 10ul of the peptide phage display library (~1011 pfu) intravenously, either retro-orbitally or 
through a tail vein injection. The M13 phage, after an intravenous injection, has a half-life of 
4.5hrs, in the circulation. Allow the mouse to recover and circulate the phage for the desired 
number of half-lives (~3-6 half-lives). 
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Isolating Cardiac Myocytes 
a. After the desired time of circulation, re-anesthetize the mouse using 2% Avertin, 
euthanize using either a CO2 chamber or cervical dislocation, and open the chest cavity. 
Now place a nick in either the right atrium or right ventricle and using a small bore 
needle, inject the left ventricle with 3-5ml of HBSS-G-Heparin, so as to flush out all the 
red blood cells from the ventricular cavity and the coronary circulation.  
b. Dissect out the heart, trim the atria and great vessels, and weigh the resulting trimmed 
heart.  
c. Place a petri dish on ice, add 2-4ml of HBSS-G-Heparin, place heart pieces in it and chop 
as finely as possible. 
d. Transfer all of this to a round bottom 5cc tube and discard the supernatant. 
e. Add 2ml of Digestion Enzyme to the pieces, incubate (with rocking) at 37˚C for 5 
minutes. 
f. Collect the supernatant into DMEM 50:50/F12/25% FBS (10ml for each heart) media; 
keep at 37˚C.  
g. Repeat the steps e-f above until all the tissue pieces are digested. 
h. Now place the accumulated tissue+DMEM+FBS through a 70µm filter. 
i. Centrifuge the filtered cells for 4 minutes at 1000rpm. 
b. Aspirate off the media, keep the pellet and resuspend the cells in 5-6ml of the plating 
medium. 
c. Now place in the cells and media in a 6” cell culture plate (to plate out the fibroblasts) 
and place in an incubator at 37˚C for 2 hours (without disturbing).  
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d. At the end of 2 hours, aspirate the top media, pellet the cells, resuspend in 1ml of PBS, 
transfer to an eppendorf tube and place in -80˚C to freeze. 
e.  Put the cell pellet through one freeze-thaw cycle to lyse the cells and release the 
internalized phage. Pellet the cell debris by centrifuging at maximum speed for 60 sec in 
a table-top centrifuge. Use 20ul of this cell lysate/supernatant to titrate the released phage 
as detailed in the phage titration section above. This phage population is the population of 
interest that will be put through subsequent cycles of phage amplification (as detailed in 
the phage amplification section above) and re-injected into a mouse for a second cycle of 
peptide phage display. The number of phage recovered from the heart will be normalized 
to the weight of the heart (in grams).    
 
Isolating Kidney Cells 
a. Inject phage library intravenously (reto-orbitally or via a tail vein injection) and allow to 
circulate for the decided number of hours. 
b. After the desired time of circulation, re-anesthetize the mouse using 2% Avertin, 
euthanize using either a CO2 chamber or cervical dislocation, and open the chest cavity. 
Now place a nick in either the right atrium or right ventricle and using a small bore 
needle, inject the left ventricle with 3-5ml of HBSS-G-Heparin, so as to flush out all the 
red blood cells from the ventricular cavity and the coronary circulation.  
c. Dissect the kidney out and rinse in PBS. 
d. In a cell culture hood, cut the kidney into small pieces with autoclaved/sterile razor blade. 
e. Digest the minced tissue with 0.75% collagenase II at 37˚C for 30 -45minutes. 
f. Pipette the digested tissue up and down. 
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g. Filter the cells with 75µm filter. 
h. Trypsinize the cells for 10minutes at room temperature. 
i. Spin down the cells and wash with PBS twice. 
j. Resuspend in 1ml of PBS. 
k. Store in eppendorf tubes at -80˚C. 
l.  Put the cell pellet through one freeze-thaw cycle to lyse the cells and release the 
internalized phage. Pellet the cell debris by centrifuging at maximum speed for 60 sec in 
a table-top centrifuge. Use 20ul of this cell lysate/supernatant to titrate the released phage 
as detailed in phage titration section above. This phage population is the control phage 
and the released phage from heart, the target organ of interest, will be expressed as a ratio 
of the number of phage recovered from kidney. The number of phage recovered from the 
kidney will be normalized to the weight of the kidney (in grams).  
m. After 3 cycles of in vivo peptide phage display, 10 plaques were picked from phage 
recovered from the target organ, amplified and sequenced as detailed in Section “Phage 
Sequencing” below. A consensus sequence emerged after 4 cycles of phage display, 
which was termed “Cardiac Targeting Peptide” or CTP, and synthesized biotinylated, 
labeled with 6-carboxyfluoroscein or as a fusion peptide with NBD or nemo-binding 
domain peptide..  
 
Phage Sequencing 
From the plate with <100 plaques, pick 10-20 for amplification and subsequent 
sequencing.  
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a. Dilute an overnight culture of E. coli 1:100 in LB. Dispense 1 ml of diluted culture into 
culture tubes, one for each clone to be characterized. 
b. Use a sterile wooden stick or pipette tip to stab a plaque from a titering plate (important: 
plates should be <1–3 days old, stored at 4°C and have <100 plaques) and transfer to a 
tube containing the diluted culture. Pick well-separated plaques. This will ensure that 
each plaque contains a single DNA sequence. 
c. Incubate the tubes at 37°C with shaking for 4.5–5 hours (no longer). 
d. Transfer the cultures to microcentrifuge tubes, and centrifuge at 14,000 rpm for 30 
seconds. Transfer the supernatant to a fresh tube and re-spin. Using a pipette, transfer the 
upper 80% of the supernatant to a fresh tube. This is the amplified phage stock and can be 
stored at 4°C for several weeks with little loss of titer. For long-term storage (up to 
several years), dilute 1:1 with sterile glycerol and store at –20°C. 
e. Transfer 500 μl of the amplified phage stock to a fresh microfuge tube. Add 200 μl of 
20% PEG/2.5 M NaCl. Invert several times to mix, and let stand for 10–20 minutes at 
room temperature. 
f. Microfuge at 14,000 rpm for 10 minutes at 4°C and discard the supernatant. Phage pellet 
may not be visible. Re-spin briefly. Carefully pipet away and discard any remaining 
supernatant. 
g. Suspend the pellet thoroughly in 100 μl of Iodide Buffer by vigorously tapping the tube. 
Add 250 μl of ethanol and incubate 10–20 minutes at room temperature. Short incubation 
at room temperature will preferentially precipitate single-stranded phage DNA, leaving 
most phage protein in solution. 
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h. Spin in a microfuge at 14,000 rpm for 10 minutes at 4°C, and discard the supernatant. 
Wash the pellet with 0.5 ml of 70% ethanol (stored at –20°C), re-spin, discard the 
supernatant, and briefly dry the pellet under vacuum or at room air. 
i. Resuspend the pellet in 30 μl of TE buffer. The template can be suspended in H2O 
instead of TE if desired, but this is not recommended for long-term storage. In TE buffer, 
the phage DNA should be stable indefinitely at –20°C. Sequence this DNA using the 
sequencing primers provided with the peptide phage display library. 
5.2 IN VITRO TRANSDUCTION EXPERIMENTS 
5.2.1 Cell transduction experiments with CTP-6CF 
In vitro cell transduction experiments were carried out using rat cardiomyoblasts (H9C2 cells), 
mouse fibroblast cell line (NIH/3T3), mouse fibrosarcoma cell line (MCA205), human epithelial 
cervical cancer cell line (HeLa cells) and human tubular kidney cell line (HK-2). Cells were 
passaged at least three times and either grown to confluence or 70% confluence (in the case of 
H9C2 cells) in the appropriate cell culture media. After at least 3 or more passages, cells were 
trypsinized, counted on a hematocytometer and plated onto collagen-coated cover-slips at a cell 
density of 2*105 cells/well in a 6-well tissue culture treated plate. Cells were left in the incubator, 
37˚C/5% CO2 overnight. Next day media was aspirated, cells washed with pre-warmed 1ml of 
Optimem and left in 1ml of Optimem. To the cells CTP-6CF was added at a final concentration 
of 50, 100 or 200uM. A negative control group of incubating only with PBS was utilized. The 
stock solution of the peptide was made in PBS at a 1mM concentration. After addition of the 
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peptide, cells were returned to the incubator for 30 minutes. After the end of the incubation 
period, media was aspirated, cells washed with pre-warmed PBS 3 times. After the washes, 1ml 
of pre-warmed 2% paraformaldehyde was added and 1ul of DRAQ5 solution, a nuclear stain, 
was added to the paraformaldehyde. This was carried out at RT for 30 minutes, light-protected. 
After 30 minutes, paraformaldehyde was aspirated, cells washed with PBS once and cover-slips 
mounted onto glass-slides using permount. The slides were kept at 4˚C, light -protected until next 
day when confocal microscopy was performed.    
For confocal microscopy, laser intensities/gains were set using negative control (PBS 
injected) cells to minimize background fluorescence. Once the laser intensity for FITC was set, it 
was kept constant across all subsequent imaging. Also serial scanning was performed to prevent 
“bleed-through” from one laser wavelength to another.  
As paraformaldehyde itself has auto-fluorescence, and boiling it can cause 
polymerization of the individual molecules forming large complexes that can precipitate at lower 
temperatures and cause fluorescence artifact, the protocol given below for making 
paraformaldehyde was followed. The 8% stock solution was stored at 4˚C, light -protected, 
wrapped in foil, and diluted 4:1 in PBS down to 2% on the day of use.    
5.2.2 8% Paraformaldehyde stock solution 
1. For each 100mls of Paraformaldehyde, add 8 grams of paraformaldehyde resin to 70 ml 
of distilled water.  
2. Heat to 70˚C (it will not dissolve).  
3. Add 1M NaOH drop by drop until the solution clears; usually requires a couple of drops.  
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4. Cool to room temperature.  
5. Add 9mls of 1x PBS or 30 mls of 0.3M PBS  
6. PH to 7.4  
7. Filter and store at 4˚C, light-protected, wrapped in foil.   
8. On the day of use, dilute necessary amount of 8% paraformaldehyde down to 2% with a 
4:1 dilution with PBS.  
5.3 METHODOLOGY FOR TRANSFECTION OF CELLS AND INHIBITION OF 
NF-ΚB ACTIVATION 
5.3.1 Materials  
Materials specified are for 1 well of a 12-well plate. Scale up or down as necessary for 
the size of the well and multiply by the number of wells needed. For example, one well of a 96-
well plate will need 6.25ul of Optimem. If the experiment is to be done in quadruplicate, would 
need 25ul for each group in the experiment.  
  
50ul of Optimem/well 
2ul of Lipofectamine/well 
200ng of reporter plasmid DNA/well (plasmid expressing Luciferase under an NF-κB 
promoter site) 
200ng of Renilla (control plasmid)/well 
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5.3.2 Methods 
1. After 3-4 cell passages, split cells using Trypsin/EDTA, and plate onto a 96-well plate at 
a cell density of 2*104/well. Return cells to the incubator. 
2. Next day incubate relevant amount of Optimem and with Lipofectamine at RT for 5 mins 
(for every 50ul of Optimem use 2ul of Lipofectamine).. 
3. Simultaneously incubate Optimem with the reporter plasmid DNA and the Renilla 
control plasmid, (ratio of 50ul of Optimem with 200ng of reporter plasmid DNA and 
200ng of Renilla control plasmid), at RT for 5 mins.  
4. Add 1 and 2 together in a 1:1 ratio and incubate at RT for 20 minutes. 
5. While above incubation is going on, aspirate media from cells, wash 3x with pre-warmed 
antibiotic-free media and leave cells in 1ml of the antibiotic-free media (1ml for a 12-
well plate; 125ul for a 96-well plate). 
6. Add 12.5ul of the optimem+lipofectamine+DNA into each well of a 96-well plate (100ul 
per well of a 12-well plate) and leave in incubator o/n. 
7. Next day, aspirate media, wash cells with pre-warmed Optimem once, and leave in 100ul 
of Optimem (for a 96-well plate). Add the peptides in the concentrations being tested and 
return cells to incubator for 30 minutes (or varying time-points as the experiment’s 
hypothesis dictates).  
8. Add murine (for H9C2 cells) or human TNFα (HeLa cells) at a concentration of 10ng/ml 
and return cells to incubator for 3 hours. 
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9. At the end of 3 hours, aspirate media, wash cells with pre-warmed PBS once, lyse cells 
with 100ul of cell lysis buffer for 5 minutes. Pipette up and down a few times to complete 
the lysis and add lysate to eppendorf tubes. Spin the debris down in a table-top 
centrifuge, at maximum speed (usually 14,000 rpm) for 5 minutes, and transfer 10uleach 
into two glass tubes for Luciferase and Renilla reading. The Luciferase and Renilla 
activity is read in a Luminometer using Luciferase and Renilla substrate.  
5.4 MOUSE INFARCT MODEL 
The following protocol for generating infarcts in mice was utilized and kept consistent from one 
set of experiments to another and between groups. Female, Balb/c, 10-20 week old mice were 
used. Female mice were chosen because of the ability to house 5/cage, as opposed to male mice 
(4/cage) and more importantly because female mice are able to tolerate cardiac insults better with 
lower post-operative mortality [125]. Mice were anesthetized with intraperitoneal (i.p.) injection 
of 2.5% Avertin (a mixture of 15.5 ml tert-amyl alcohol to 25 grams of 2-2-2 Tribromoethanol - 
stock solution diluted to 2.5% concentration with PBS) at a dose of 15ul/gm of body weight. 
Adequate anesthetic level was assessed by lack of response to toe-pinch and lack of a gag reflex. 
Mice were intubated, using direct visualization of the vocal chords, with a 22G cannula and 
placed on a Harvard rodent ventilator apparatus. Tube placement was confirmed by symmetric 
expansion of the thoracic cavity. Mice were ventilated with ~0.1cc/breath tidal volume at a rate 
of 110 breaths/minute. 
Following successful intubation/ventilation, the chest cavity was opened using a left 
lateral ternotomy approach. Care was taken not to extend the surgical incision cephalad to the 
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level of the sternal head, as a large venous confluence is present in that region and cutting 
through them can lead to major, exsanguinating bleed. A self-retaining mouse retractor was 
placed inside the incision and the teeth opened to reveal the anterior surface of the heart. The 
pericardium was gently removed with blunt forceps. A suture, 6-0 prolene, blue, monofilament 
(Owens & Minor: #8714H) was placed along the lateral wall of the left ventricle (LV), ~2mm 
below the lowest dip of the left atrium and ligated with exactly 5 squarely-placed knots. Ischemia 
was confirmed by the resulting pallor of the myocardium and development of wall motion 
abnormality. The muscle layer and skin were closed in two layers with running sutures with 8-0 
black, monofilament nylon suture (Owens& Minor: #2808G). The mice were extubated once 
spontaneous breathing was confirmed, and recovered on a heating pad. Post-operative pain was 
managed with subcutaneous injection of Ketoprofen, 5mg/Kg, on post-op day 0, 1 and 2 or with 
subcutaneous Buprenorphine, at a dose of 0.1mg/Kg body weight given once on the day of 
surgery and twice daily on post-op day 1 and 2. Mice also got one injection of subcutaneous 
Ampicillin, 100mg/Kg, after surgery for prophylaxis against post-surgical infection. Right after 
ligation and suture placement on the anterior surface of the heart to produce myocardial 
infarction, and before closing the chest wall, mice received i.p. peptides in different doses. The 
surgeon (myself) was always blinded to the treatment. Also surgeries were carried out in a 
rotational fashion so that any variation due to surgical technique was distributed equally over the 
treatment groups. 
Mice were euthanized on post-operative day 7. On day of euthanasia, mice were 
anesthetized, chest cavity opened, and 1cc of 1M KCl injected via the right ventricle (RV) in 
order to arrest the heart in diastole to prevent contraction band necrosis. This was followed by 
injecting, through the right ventricle, 5cc of Glyo-fixx (formalin-substitute), heart dissected out 
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and placed in 15ml of Glyo-fixx, until tissue embedded for sectioning. After paraffin embedding, 
cross-sections of the heart were taken starting at the apex. The first section was taken once the 
LV cavity appeared, with second and third sections taken 10 microns apart and cephalad of the 
first section. The three sections were H&E stained, light microscopy photographs taken, and area 
of infarct in each section mapped out using computer software Metamorph and expressed as a 
percent of the whole heart. The infarct area from the three sections was averaged to give the final 
infarct size for each mouse.  
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